ribavirin has been researched along with Cirrhosis, Liver in 1057 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (1.70) | 18.2507 |
| 2000's | 303 (28.67) | 29.6817 |
| 2010's | 674 (63.77) | 24.3611 |
| 2020's | 62 (5.87) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA | 1 |
| Carrilho, FJ; Cunha-Silva, M; Lima, RGR; Lourenço, MS; Mazo, DF; Oliveira, AIN; Oliveira, CP; Pessoa, MG; Sevá-Pereira, T; Souza, EO; Zitelli, PMY | 1 |
| Jang, JY; Jun, DW; Jung, YK; Kim, MY; Kim, SG; Kwon, OS; Lee, JW; Lee, SH; Park, JY; Yoo, HW | 1 |
| Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J | 1 |
| Nguyen, MH; Wong, YJ | 1 |
| Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH | 1 |
| Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| Kao, JH; Liu, CH; Liu, CJ | 1 |
| Boettler, T; Emmerich, F; Fischer, N; Gundlach, S; Hofmann, M; Huang, J; Huzly, D; Kemming, J; Llewellyn-Lacey, S; Lütgehetmann, M; Neumann-Haefelin, C; Panning, M; Pischke, S; Price, DA; Schulze Zur Wiesch, J; Tanriver, Y; Thimme, R; Warnatz, K | 1 |
| Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S | 1 |
| Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A | 1 |
| Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D | 1 |
| Fernandes, F; Pereira, G; Perez, R; Piedade, J; Victor, L; Villela-Nogueira, CA | 1 |
| Balbi, E; Cardoso, SW; Carius, L; Grinsztejn, B; Halpern, M; Pacheco, L; Perazzo, H; Pinto, L; Roma, J; Veloso, VG | 1 |
| Abdel-Rahman, YO; Abdel-Razik, W; Dabbous, HM; Elakel, W; Elmakhzangy, H; Elshafaey, A; Esmat, G; Ismail, SA; Omar, H; Saeed, R; Salama, R; Waked, I; Ziada, DH | 1 |
| Berak, H; Brzdęk, M; Citko, J; Dybowska, D; Flisiak, R; Garlicki, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Lorenc, B; Mazur, W; Parfieniuk-Kowerda, A; Piekarska, A; Tomasiewicz, K; Tronina, O; Zarębska-Michaluk, D | 1 |
| Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E | 1 |
| Hussain, N; Iqbal, M; Mahnoor, M; Maqsood, Q; Sumrin, A; Wajid, A; Younas, S | 1 |
| Ahmad, B; Ahmad, J; Ahmad, L; Bashir, K; Chen, TW; Hameed, H; Haq, I; Haq, M; Hussain, K; M Aljowaie, R; Malik, G; Maryam, A; Mohsen Abougazia, E; Ullah, A | 1 |
| Dong, G; Jiang, J; Li, J; Li, X; Long, S; Su, M; Wei, Y; Zhou, Y | 1 |
| Li, H; Liu, Z; Ma, C; Wang, J; Wang, X; Wang, Y; Xu, X | 1 |
| Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA | 1 |
| Chaiyabutr, C; Charoenpipatsin, N; Chularojanamontri, L; Nimanong, S; Silpa-Archa, N; Wongpraparut, C | 1 |
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| Avram, L; Craciun, R; Crisan, D; Crisan, N; Epure, F; Grigorescu, M; Grigorescu, MD; Leach, N; Lupsor, M; Radu, C; Suciu, A | 1 |
| Costa, J; Forns, X; García-López, M; Lens, S; Navasa, M; Pérez-Del-Pulgar, S; Sastre, L | 1 |
| Abutidze, A; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Ezugbaia, M; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kvaratskhelia, V; Metreveli, D; Morgan, J; Nasrullah, M; Shadaker, S; Sharvadze, L; Tsertsvadze, T | 1 |
| Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S | 1 |
| Cui, LY; Liu, LD; Nan, YM; Zhao, W | 1 |
| Pawlotsky, JM | 1 |
| Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ | 1 |
| Aleman, S; Björkström, NK; Carlsson, T; Falconer, K; Gorin, JB; Malone, DFG; Sandberg, JK; Strunz, B | 1 |
| Sirinawasatien, A; Techasirioangkun, T | 1 |
| Cheng, X; Du, LY; Liao, J; Ma, YJ; Tang, H; Xie, WW; Yan, LB | 1 |
| Abou-Samra, AB; Butt, AA; Nasir, B; Rasool, S; Rubi, G; Tayyab, GUN | 1 |
| Dalton, HR; Donnelly, M; Fraser, A; Guaci, J; Gunson, R; Hussaini, SH; Kemp, L; Lin, N; Miller, M; Murray, A; Simpson, K; Spoor, J; Stanley, A; Swann, R; Wallace, SJ | 1 |
| Alhaddad, O; Elsabaawy, D; Elsabaawy, M; Elshazly, H; Khalil, F; Rady, M; Sabry, A; Shebl, N; Wahb, A | 1 |
| Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL | 1 |
| Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M | 1 |
| Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA | 1 |
| Geller, J; Jakovleva, J; Kurtenkov, O; Sergejev, B | 1 |
| An, Y; Jia, L; Li, X; Liu, Q; Luo, G; Ouyang, J; Song, R; Zhang, B; Zhang, R | 1 |
| Abuelhassan, WB; Ally, R; Gasim, GI; Menezes, C | 1 |
| Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T | 1 |
| Barrett, BK; Chan, J; Feld, JJ; Hamadeh, A; Kim, JJ; Wong, WWL | 1 |
| Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Estévez Escobar, M; Gómez Torres, KM; Lozano Serrano, AB | 1 |
| Farooq, MO; Malik, K; Mengal, FUA; Salim, A | 1 |
| Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iliescu, L; Istratescu, D; Manuc, M; Pop, CS; Preda, CM; Tieranu, C; Voiosu, T | 1 |
| Bourliere, M; Buti, M; Chokkalingam, A; Colombo, M; Esteban, R; Gaggar, A; Henry, L; Mangia, A; Manns, M; Muir, A; Nader, F; Papatheodoridis, GV; Racila, A; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Batista, AD; Carvalho, BT; Filgueira, NA; Lacerda, C; Lacerda, HR; Lima, K; Lima, MS; Lopes, EP; Medeiros, TB; Melo, CRL; Santos, JC; Silva, IPL | 1 |
| Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I | 1 |
| Chuma, M; Fukuda, H; Hara, K; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Tanaka, K; Yamanaka, T | 1 |
| Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R | 1 |
| Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT | 1 |
| Chemych, MD; Lishnevska, AG | 1 |
| Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y | 1 |
| Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS | 1 |
| Boglione, L; Cardellino, CS; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Falade-Nwulia, O; Fried, MW; Nelson, DR; Segal, JB; Suarez-Cuervo, C; Sulkowski, MS | 1 |
| Bansal, A; Dutta, U; Goyal, O; Grover, R; Kishore, H; Malhi, NS; Nanda, V; Saluja, H; Sehgal, A; Sidhu, JS; Sidhu, S; Sidhu, SS; Singh, G; Singh, R | 1 |
| Bider-Canfield, Z; Cheetham, TC; Gharibian, D; Latt, NL; Louie, V; Mittal, R; Sahota, A; Yanny, BT | 1 |
| Brown, RS; Charlton, M; Curry, MP; Hunt, S; O'Leary, JG; Stepanova, M; Younossi, ZM | 1 |
| Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N | 1 |
| Aghemo, A; Boccaccio, V; Bruno, S; Cabibbo, G; Calvaruso, V; Colombo, M; Craxì, A; Crosignani, A; Di Marco, V; Giacomelli, L; Iavarone, M; Maisonneuve, P; Roffi, L; Rossi, S | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Degasperi, E | 1 |
| Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A | 1 |
| Akriviadis, E; Arvaniti, P; Bellou, A; Dalekos, GN; Goulis, I; Karatapanis, S; Kattamis, A; Koskinas, J; Kountouras, D; Kourakli, A; Maragkos, K; Papatheodoridis, GV; Petropoulou, F; Sinakos, E; Tampaki, M; Toli, B; Triantos, C; Tsiaoussis, G; Vassiliadis, T; Vlachaki, E; Zachou, K | 1 |
| Carmona-Soria, I; Caunedo-Alvarez, A; Cordero-Ruiz, P; Flores-Cucho, A; Quezada-Pacheco, RH; Rodríguez-Téllez, M; Romero-Gómez, M; Vilches-Arenas, Á | 1 |
| Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E | 1 |
| Aghemo, A; Alberti, A; Antinori, A; Ascione, A; Bruno, R; Bruno, S; Chirianni, A; Craxì, A; Gaeta, GB; Giannini, EG; Marzioni, M; Merli, M; Messina, V; Montilla, S; Pani, L; Perno, CF; Petta, S; Puoti, M; Raimondo, G; Rendina, M; Russo, P; Silberstein, FC; Villa, E; Zignego, AL | 1 |
| Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A | 1 |
| Bailey, R; Borgia, S; Brainard, DM; Cooper, C; Elkhashab, M; Feld, JJ; Greenbloom, S; Huang, KC; Huchet, E; Hyland, RH; Marotta, P; Massetto, B; McHutchison, JG; Ramji, A; Shafran, SD; Svarovskaia, ES; Swain, MG; Tam, E; Vachon, ML; Willems, B; Yoshida, EM; Yun, C | 1 |
| Metreveli, D; Ruadze, E; Sharvadze, L; Tsertsvadze, T | 1 |
| Andriulli, A; Guarino, M; Morisco, F | 1 |
| Alavian, SM; Rezaee-Zavareh, MS | 1 |
| Kaabi, SA; Singh, R; Soofi, ME; Thandassery, RB; Tharian, B | 1 |
| Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H | 1 |
| Aggarwal, R; Bhargava, R; Goel, A; Rai, P | 1 |
| Caruso, V; Cenderello, G; Copetti, M; Forni, G; Gamberini, R; Ganga, R; Mangia, A; Piazzolla, V; Piga, A; Quarta, A; Santoro, R; Sarli, R | 1 |
| Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Lin, KH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Abdel Alem, S; Abdellatif, Z; Adel, E; Elsharkawy, A; Esmat, G; Fouad, R; Hussein, MS; Musa, S; Nagy, A; Yosry, A | 1 |
| Lin, HC; Su, CW; Yang, YY | 1 |
| Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P | 1 |
| Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S | 1 |
| Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP | 1 |
| Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM | 1 |
| Ardévol, M; López, D; Masnou, H; Morillas, RM | 1 |
| Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D | 1 |
| Bian, DD; Chen, Y; Duan, C; Duan, ZP; Jiang, YY; Liu, M; Liu, S; Wang, T; Wang, Z; Zhang, JY; Zheng, SJ; Zhou, HY | 1 |
| Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T | 1 |
| Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A | 1 |
| Abaci, N; Akyuz, F; Akyuz, U; Besisik, F; Cakiris, A; Ciftci, S; Demir, K; Kaymakoglu, S; Keskin, F; Ustek, D | 1 |
| Arends, JE; Bijmolen, M; Blokzijl, H; Burger, DM; de Kanter, CTMM; de Knegt, RJ; Dofferhoff, ASM; Drenth, JPH; Lieveld, FI; Maan, R; Smolders, EJ; van der Valk, M; van Erpecum, KJ; van Tilborg, M | 1 |
| Rostkowska, K; Simon, K; Szymanek-Pasternak, A | 1 |
| Caraceni, P; Carrai, P; Donato, MF; Fagiuoli, S; Filì, D; Gianstefani, A; Martini, S; Mazzarelli, C; Melazzini, M; Montilla, S; Pani, L; Petraglia, S; Rendina, M; Russo, P; Trotta, MP; Visco-Comandini, U | 1 |
| Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX | 1 |
| Abravanel, F; Barragué, H; Champagne, E; Condat, B; Izopet, J; Petitdidier, N; Renou, C | 1 |
| Abdalla, U; Abdel-Khalek, EE; Abdel-Wahab, M; Al-Refaey, AK; Al-Shobari, M; Ali, M; El-Gilany, AH; Elghawalby, AN; Elmorshedi, M; Sadani, M; Salah, T; Shiha, U; Sultan, AM; Yassen, AM | 1 |
| Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Manns, MP; Port, K; Schlevogt, B; Solbach, P; Wedemeyer, H | 1 |
| Abd-Elsalam, S; Ahmad, YK; Badawi, R; Elfert, A; Sharaf-Eldin, M; Soliman, S | 1 |
| Aburawash, A; Elsisi, GH; Waked, E | 1 |
| Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH | 1 |
| Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E | 1 |
| Lagging, M; Waldenström, J | 1 |
| Ferenci, P; Gschwantler, M; Gutic, E; Haltmayer, H; Kozbial, K; Laferl, H; Lang, T; Luhn, J; Moser, S; Reiberger, T; Schleicher, M; Schubert, R; Schütz, A; Schwabl, P; Schwanke, C; Steindl-Munda, P | 1 |
| Al-Zoairy, R; Beinhardt, S; Datz, C; Ferenci, P; Graziadei, I; Gschwantler, M; Hofer, H; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Schwarzer, R; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Trauner, M; Zoller, H | 1 |
| Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
| AbdAllah, M; Doss, W; El Akel, W; El Kassas, M; El Shazly, H; El Shazly, Y; Elbaz, T; Elsaeed, K; Esmat, G; Gomaa, AA; Ismail, SA; Korany, M; Nasr, A; Omar, H; Said, M; Shaker, MK; Waked, I; Yousif, M | 1 |
| Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U | 1 |
| Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Kinh, N; Lai, CL; Lai, W; Lim, YS; Stepanova, M; Younossi, ZM; Yuen, MF | 1 |
| Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A | 1 |
| Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Wu, CK; Ye, YH | 1 |
| Asselah, T; Bellissant, E; Bourlière, M; Bronowicki, JP; Canva, V; Diallo, A; Fontaine, H; Laforest, C; Leroy, V; Loustaud-Ratti, V; Ouzan, D; Petrov-Sanchez, V; Renault, A; Roulot, D; Rousseau, C; Schischmanoff, O; Serfaty, L; Thibault, V; Zoulim, F | 1 |
| Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM | 1 |
| Alavi, M; Dore, GJ; Law, MG | 1 |
| Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT | 1 |
| Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Amador, C; Carmena, J; Flores, J; Galindo, MJ; García-Deltoro, M; Masiá, M; Mínguez, C; Montero, M; Ortega, E; Reus, S | 1 |
| El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ohya, K; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Dohmen, K; Ichiki, Y; Ishibashi, H; Kawano, A; Miki, K; Morita, C; Nomura, H; Shigematsu, H; Shimoda, S; Takahashi, K; Yanagita, K | 1 |
| Chen, CY; Chen, MY; Chen, Q; Kao, JH; Peng, CY; Tang, H; Wu, JJ; Yu, ML | 1 |
| Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A | 1 |
| Fan, R; Hou, J; Liang, X; Sun, J | 1 |
| Asante-Appiah, E; Asselah, T; Barr, E; de Ledinghen, V; Gerstoft, J; Hwang, P; Nguyen, BY; Pockros, PJ; Reesink, H; Robertson, M; Serfaty, L; Talwani, R; Wahl, J | 1 |
| Agarwal, K; Asante-Appiah, E; Barclay, S; Barr, E; Brown, AS; Collier, J; Cramp, ME; Du, J; Forton, DM; Foster, GR; Fox, R; Gilbert, CL; Gordon, F; Haber, B; Moreea, S; Mutimer, DJ; Robertson, MN; Rosenberg, WM; Ryder, SD; Ustianowski, A; Wahl, J | 1 |
| Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P | 1 |
| Aghemo, A; Baldanti, F; Borghi, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Lampertico, P; Lunghi, G; Novazzi, F; Paolucci, S; Perbellini, R | 1 |
| Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T | 1 |
| Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R | 1 |
| Ansari, MA; Barnes, E; Bowden, R; Hudson, E; Klenerman, P; Marchi, E; Mclean, A; Pedergnana, V; Ramamurthy, N; Spencer, CCA | 1 |
| Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE | 1 |
| Masumoto, A; Miyazaki, M; Motomura, K; Tanaka, K; Yada, M | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A | 1 |
| Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML | 1 |
| Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T | 1 |
| Gupta, E; Kataria, A; Nayak, SL; Sarin, SK | 1 |
| Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M | 1 |
| Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM | 1 |
| Bogomolov, PO; Chen, X; Enejosa, JV; Isakov, V; Maevskaya, MV; Ogurtsov, P; Paduta, D; Pasechnikov, V; Shulman, NS; Viani, RM; Znoyko, O | 1 |
| Boscarino, JA; Daida, YG; Gordon, SC; Holmberg, SD; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Xing, J; Zhong, Y | 1 |
| Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL | 1 |
| Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ | 1 |
| Berg, CP; Berg, T; Blessin, U; Engelmann, C; Grottenthaler, JM; Harrer, E; Hinterleitner, C; Lauer, UM; Malek, NP; Pathil, A; Sarrazin, C; Scholten, S; Schott, E; Seybold, U; Spengler, U; Steurer, M; Stremmel, W; von Hahn, T; Wedemeyer, H; Welker, MW; Werner, CR | 1 |
| Höner Zu Siederdissen, C; Maasoumy, B | 1 |
| Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Alami, NN; Allam, N; Esmat, G; Fouad, R; Hall, C; Hassany, M; Kopecky-Bromberg, S; Mobashery, N; Mohey, M; Qaqish, RB; Shiha, G; Soliman, R; Waked, I | 1 |
| Bhamidimarri, KR; Chu, D; Han, SB; Hu, KQ; Lee, TP; Ma, X; Mohanty, SR; Pan, CQ; Park, J; Tiongson, BC; Tong, M; Wang, D; Xiao, PY | 1 |
| Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I | 1 |
| Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G | 1 |
| Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R | 1 |
| But, DYK; Chan, CW; Chan, HLY; Chan, JMC; Cheung, WI; Chow, WH; Fan, TTT; Fung, JYY; Hui, AJ; Hui, YT; Kung, KN; Lai, KB; Lai, LSW; Lai, MS; Lam, BCY; Lam, JTW; Lam, K; Lao, WC; Lau, JYL; Leung, NWY; Li, MKK; Liu, K; Liu, SD; Loo, CK; Lui, TKL; Luk, WF; Ma, YK; Mak, WY; Ng, ACY; Shan, EHS; Tong, RKN; Tsang, OTY; Tsang, SWC; Wong, GLH; Wong, VWS; Yuen, MF | 1 |
| Al-Deen Abead, M; Baraka, MA; Gomaa, AA; Hussein, AK; Wahsh, EA | 1 |
| Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP | 1 |
| Bischoff, J; Rockstroh, JK | 1 |
| Jacobson, IM | 1 |
| Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Hwang, SG; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Lee, YB; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Chang, CH; Chen, DS; Chen, PJ; Hong, CM; Huang, YJ; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Su, TH; Sun, HY; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES | 1 |
| Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M | 1 |
| Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC | 1 |
| Ghesquiere, W; Huhn, GD; Linaberry, M; McPhee, F; Noviello, S; Poordad, F; Ramji, A; Shafran, SD; Shiffman, ML; Wong, A; Wong, F; Yang, R | 1 |
| Avril, E; Bouscaillou, J; Butsashvili, M; Etienne, A; Gamezardashvili, A; Inaridze, I; Kamkamidze, G; Kharshiladze, D; Kikvidze, T; Labartkava, K; Le Pluart, D; Luhmann, N | 1 |
| De Maria, C; Ghidotti, I; Giannini, EG; Grillo, F | 1 |
| Bair, MJ; Chen, HL; Cheng, CH; Chu, CY; Lee, YK; Lin, IT; Wu, CH | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lin, MT; Lu, SN; Sou, FM; Tsai, MC; Wang, JH; Wu, CK; Yen, YH | 1 |
| Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S | 1 |
| Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM | 1 |
| Kimura, K | 1 |
| Affonso-de-Araújo, ES; Álvares-da-Silva, MR; Alves, K; Brandão-Mello, CE; Cheinquer, H; Coelho, HS; Cohen, DE; Ferraz, ML; Ferreira, PRA; Furtado, J; Lari, SA; Liu, L; Martinelli, A; Mendes-Correa, MC; Nunes, EP; Parana, R; Pessoa, MG; Pilot-Matias, T; Ramalho-Madruga, JV; Shulman, NS; Silva, G; Tripathi, R | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lu, SN; Wang, JH; Yen, YH | 1 |
| Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Berger, F; Boesecke, C; Buendgens, L; Christensen, S; Hüppe, D; Ingiliz, P; Lutz, T; Mauss, S; Schewe, K; Simon, KG; Tacke, F | 1 |
| Basha, MAA; Bassiony, MA; Hanafy, AS | 1 |
| Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I | 1 |
| Cho, M; Han, SY; Heo, J; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Pyeon, SI; Song, GA; Woo, HY | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Wang, YJ; Wu, SH | 1 |
| Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H | 1 |
| Babudieri, S; Barbarini, G; Candilo, FD; Cariti, G; Dell'Isola, S; Distefano, M; Ettorre, GM; Fontanella, L; Giannelli, V; Iovinella, V; Ippolito, AM; Izzi, A; Marignani, M; Messina, V; Moretti, A; Palitti, VP; Pellicelli, A; Pompili, M; Scifo, G; Tarquini, P; Vennarecci, G; Vignally, P | 1 |
| Cenderello, G; Ciancio, A; Copetti, M; Lorusso, C; Mangia, A; Minisini, R; Orlandini, A; Piazzolla, V; Santoro, R; Squillante, MM; Verucchi, G | 1 |
| Maasoumy, B; Manns, MP; Sandmann, L | 1 |
| Choi, JW; Ko, SY; Seo, HY; Seo, MS; Yoon, SY | 1 |
| Chen, CH; Chien, RN; Hsieh, SY; Hu, TH; Hung, CH; Lin, CL; Lin, CY; Lu, SN; Sheen, IS; Tung, SY | 1 |
| Chtioui, H; Fraga, M; Gouttenoire, J; Marcu, C; Moradpour, D; Pascual, M; Sahli, R; Vionnet, J | 1 |
| Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X | 1 |
| Baicus, C; Constantinescu, I; Diculescu, M; Dumitru, R; Gavrila, D; Istratescu, D; Manuc, M; Manuc, T; Oproiu, A; Preda, CM; Sandra, I; Tieranu, C; Vasilescu, C; Voiosu, T | 1 |
| Frosi, A; Frosi, G; Meloni, MF | 1 |
| Kanda, T; Kaneko, T; Komoriya, T; Kuroda, K; Matsumoto, N; Matsuoka, S; Moriyama, M; Nakajima, N; Nirei, K; Ogawa, M; Shibata, T; Takayama, T; Tamura, A; Yamamoto, T; Yamazaki, M | 1 |
| Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S | 1 |
| Davis, GL; Klintmalm, GB; McKenna, GJ; O'Leary, JG | 1 |
| Blum, R; Kessebohm, K; Pfaundler, N; Stickel, F; Stieger, M | 1 |
| de los Santos-Gil, I; Gea, I; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merchante, N; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F; Torres-Cornejo, A | 1 |
| Agarwal, K; Carey, I; Joshi, D | 1 |
| Bani-Sadr, F; Carrieri, P; Dabis, F; Loko, MA; Marchou, B; Morlat, P; Neau, D; Pambrun, E; Salmon, D; Winnock, M | 1 |
| Jia, JD; Rakhda, MI; Wang, TI; Zhao, XY | 1 |
| Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT | 1 |
| Abdel-Rahman, M; El-Akel, W; El-Beshlawy, M; El-Raziky, M; Esmat, G; Saad, Y; Said, M; Zayed, N | 1 |
| Avellón, A; Barreiro, P; Cifuentes, C; Echevarría, JM; Macías, J; Martín-Carbonero, L; Neukam, K; Pineda, JA; Soriano, V; Vargas, J | 1 |
| Aguilera, V; Berenguer, M; Vinaixa, C | 1 |
| Arterburn, S; Brainard, D; Davis, MN; Gane, EJ; Gordon, SC; Hassanein, T; Hyland, RH; Jacobson, IM; Jiang, D; Kayali, Z; Kowdley, KV; Lawitz, E; Mangia, A; McHutchison, JG; McNally, J; Nyberg, L; Reddy, KR; Rodriguez-Torres, M; Schultz, M; Sheikh, AM; Subramanian, GM; Symonds, WT; Wyles, D; Younossi, Z | 1 |
| Al-Assi, MT; An, D; Bennett, M; Brainard, D; Everson, G; Feld, J; Gordon, SC; Jacobson, IM; Kowdley, KV; Lawitz, E; Lin, M; McHutchison, JG; McNally, J; Nelson, DR; Patel, K; Pianko, S; Rodriguez-Torres, M; Schiff, E; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Symonds, WT; Yoshida, EM | 1 |
| Aouri, M; Buclin, T; Cavassini, M; Csajka, C; Decosterd, LA; Mercier, T; Moradpour, D; Rauch, A; Telenti, A | 1 |
| Chang, B; Li, B; Sun, Y; Teng, G; Zhang, W; Zhao, J | 1 |
| Arena, U; Corti, G; Laffi, G; Leoncini, L; Marra, F; Milani, S; Monti, M; Pellegrini, E; Pinzani, M; Renzo, S; Stasi, C; Triboli, E; Zignego, AL | 1 |
| Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourlière, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Dao, T; de Ledinghen, V; Di Martino, V; Dorival, C; Feray, C; Fontaine, H; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Métivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Serfaty, L; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Abdel-Rahman, M; El Raziky, M; El-Akel, W; El-Sayed, M; Elsharkawy, A; Esmat, G; Ghoneim, H; Khattab, H | 1 |
| Auriemma, F; Caporaso, N; Donnarumma, L; Gaeta, L; Gentile, I; Granata, R; Guarino, M; Loperto, I; Morisco, F; Stroffolini, T | 1 |
| Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Iio, S; Imai, Y; Inada, M; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Abbas, SM; El-Feky, HM; Hegab, MF; Lashin, AH; Metwally, MA; Shaheen, YA | 1 |
| Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A | 1 |
| Belleli, D; Davis, AK; Kemp, W; McCarthy, P; Northcott, MJ; Ong, WL; Street, A; Tran, H; Walsh, M | 1 |
| Annicchiarico, EB; D'Aversa, F; Gasbarrini, A; Pompili, M; Ponziani, FR; Siciliano, M | 1 |
| Baumgarten, A; Boesecke, C; Grzeszczuk, A; Mandorfer, M; Meyer-Olson, D; Neukam, K; Payer, BA; Peck-Radosavljevic, M; Pineda, JA; Puoti, M; Reiberger, T; Rivero, A; Rockstroh, JK; Trauner, M; Zangerle, R | 1 |
| Kang, EJ; Kweon, YO; Lee, HS; Lee, YL; Park, HW; Park, SY; Tak, WY; Yang, HM | 1 |
| Horváth, G; Hunyady, B; Makara, M; Szalay, F; Tornai, I | 1 |
| Battegay, M; Beniowski, M; Grint, D; Jevtovic, D; Kirk, O; Lundgren, JD; Mocroft, A; Peters, L; Pradier, C; Rockstroh, JK; Schwarze-Zander, C; Soriano, V | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strasser, M; Trauner, M; Wrba, F | 1 |
| Aichelburg, MC; Breitenecker, F; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scheiner, B; Trauner, M | 1 |
| Abbasi, A; Bhutto, AR; Butt, N; Dhillo, AK; Munir, SM | 1 |
| Del Rio Martin, J; Fiel, MI; Satapathy, SK; Schiano, TD; Vanatta, JM | 1 |
| Ahmed, DS; Barua, R; Chowdhury, MS; Ishaque, SM; Masud, H; Parveen, S; Rahman, MA; Rahman, MZ | 1 |
| Aziz, S; Mirza, T; Sohail, S | 1 |
| Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S | 1 |
| Aghemo, A; Cheroni, C; Colombo, M; De Francesco, R; De Nicola, S; Degasperi, E; Galmozzi, E; Grassi, E; Rumi, MG; Valenti, L | 1 |
| Arakawa, Y; Higuchi, T; Matsumura, H; Moriyama, M; Nakamura, H; Nirei, K; Ogawa, M; Tanaka, N | 1 |
| Armienta-Sarabia, R; Cordero-Pérez, P; Hernández-Gómez, ME; Malé-Velázquez, R; Marín-López, E; Muñoz-Espinosa, LE; Núñez-Camarena, Jde J; Olivera-Martínez, MA; Sánchez-Avila, JF; Torres-González, L | 1 |
| Cabezas, J; Crespo, J; Luis Calleja, J; Selmo, J | 1 |
| Forns, X; Solà, R | 1 |
| Planas, R; Tural, C | 1 |
| Macías, J; Rivero, A | 1 |
| Aizawa, N; Enomoto, H; Iijima, H; Ikeda, N; Imanishi, H; Iwata, K; Iwata, Y; Nishiguchi, S; Saito, M; Sakai, Y; Takashima, T; Tanaka, H | 1 |
| Fabri, M; Kiralj, K; Mikić, SS; Preveden, T; Ruzić, M; Vukadinov, T | 1 |
| Agarwal, K; Barnabas, A | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 1 |
| Khokhar, N; Niazi, TK; Qureshi, MO | 2 |
| Bansal, M; Bichoupan, K; Branch, AD; Crismale, JF; Dieterich, DT; Liu, LU; Martel-Laferrière, V; Odin, JA; Pappas, A; Perumalswami, PV; Schiano, TD; Schonfeld, E; Wyatt, C | 1 |
| Chen, XY; He, ZM; Hua, W; Ma, LN | 1 |
| Barnard, RJ; Bhanja, S; Bourque, M; DiNubile, MJ; Gane, EJ; Hwang, PM; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A; Strizki, J; Zhou, A | 1 |
| Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY | 1 |
| Caruz, A; Cifuentes, C; Macías, J; Mira, JA; Neukam, K; Pineda, JA; Real, LM; Rivero, A; Rivero-Juarez, A; Soriano, V | 1 |
| Deguchi, H; Higashi, K; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawaguchi, M; Kawashima, A; Maekita, T; Mori, Y; Moribata, K; Shingaki, N; Tamai, H; Tsukuda, H; Ueda, K | 1 |
| Ackefors, M; Gjertsen, H; Nyström, J; Sönnerborg, A; Weiland, O; Wernerson, A | 1 |
| Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Sánchez-Parra, C; Soriano, V; Treviño, A; Vispo, E | 1 |
| Abdurakhmanov, D; Colombo, M; DeMasi, R; Fernández, I; Ferreira, PA; Hill, A; Iraqi, W; Läuffer, JM; Lonjon-Domanec, I; Moreno, C; Strasser, SI; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H | 1 |
| Abdo, S; Attia, D; El Akel, W; El Raziky, M; Elsharkawy, A; Esmat, G; Khatab, H; Shaker, O | 1 |
| Anagnostou, O; Andreadis, I; Deutsch, M; Kalafateli, M; Ketikoglou, I; Manolakopoulos, S; Mela, M; Papatheodoridis, G; Pectasides, D; Schini, M; Striki, A; Triantos, C | 1 |
| Chen, CY; Chien, RN; Fang, CC; Fang, YJ; Hsu, CW; Huang, YH; Hung, CH; Lee, CM; Lu, SN; Peng, CY; Tsai, TJ; Tseng, KC; Tung, SY; Yeh, CT | 1 |
| Barluenga, E; Clotet, B; Jou, A; López, JJ; Muga, R; Ojanguren, I; Planas, R; Sanmartín, R; Sanvisens, A; Tor, J; Tural, C; Videla, S | 1 |
| Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM | 2 |
| Hörl, WH; Schmidt, A | 1 |
| Alam, S; Alexander, GJ; Bargery, C; Dearden, J; Forton, D; Foster, GR; Freshwater, D; Mills, PR; Moreea, S; Ryder, S; Shoeb, D; Vila, X; Weatherall, A; White, E | 1 |
| Casado, JL; Martí-Belda, P; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Toon, CD; Tsochatzis, E; Xirouchakis, E | 1 |
| Dusheiko, G; Ferenci, P | 1 |
| Ahlenstiel, G; Booth, DR; Douglas, MW; George, J; Leung, R; Liddle, C; O'Connor, KS; Parnell, G; Patrick, E; Read, SA; Stewart, GJ; Suppiah, V; van der Poorten, D; Yang, JY | 1 |
| Harada, N; Hayashi, N; Hiramatsu, N; Kanto, T; Miyagi, T; Miyazaki, M; Morishita, N; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y | 1 |
| Guner, R; Tufan, ZK | 1 |
| Alvarez, H; de la Llana, FG; Domingo, P; Genebat, M; Guardiola, JM; Hernández-Quero, J; Leal, M; Lluch, JF; Marín, J; Mariño, A; Martínez, L; Martínez-Madrid, O; Martínez-Pérez, MA; Ruiz-Mateos, E; Sánchez-Villegas, J; Vera, F | 1 |
| Dillon, JF; Heron, T; Miller, MH | 1 |
| Aspinall, E; Barclay, ST; Dillon, JF; Dusheiko, G; Goldberg, D; Hayes, P; Hutchinson, SJ; Innes, H; Mills, PR | 1 |
| Yang, HS; Zhang, CY; Zhang, HM; Zhang, Q | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Tsai, PC; Wang, LY; Yang, HL; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Mandorfer, M | 1 |
| Canva, V; Deltenre, P; Deuffic-Burban, S; Dhumeaux, D; Larrey, D; Mallet, V; Mathurin, P; Obach, D; Pageaux, GP; Pol, S; Roudot-Thoraval, F; Schwarzinger, M; Yazdanpanah, Y | 1 |
| Catalli, L; Chua, J; Manos, MM; Monto, A; Murphy, RC; Pauly, MP; Saxena, V; Shvachko, VA; Terrault, NA; Wayne, E; Yee, HS | 1 |
| Chen, PJ; Liu, CJ | 1 |
| Appourchaux, K; Asselah, T; Bedossa, P; Bièche, I; Broët, P; De Muynck, S; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Valla, D; Vidaud, M | 1 |
| Andriulli, A; Cozzolongo, R; Fontana, R; Iacobellis, A; Ippolito, A; Minerva, N; Niro, GA; Palmieri, O; Valvano, MR | 1 |
| Hagan, LM; Schinazi, RF; Sulkowski, MS | 1 |
| Arama, V; Brisc, C; Caruntu, F; Gheorghe, L; Goldis, A; Iacob, S; Motoc, A; Preotescu, L; Rednic, N; Rugina, S; Simionov, I; Stefan, I | 1 |
| Aguilera, I; Gómez-Bravo, MA; Núñez-Roldán, A; Sousa, JM | 1 |
| Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourliere, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Chazouilleres, O; Dao, T; De Ledinghen, V; Di Martino, V; Dorival, C; Fontaine, H; Fontanges, T; Gournay, J; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Metivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Portal, I; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Fridell, JA; Ghabril, M; Joseph Tector, A; Kwo, PY; Lacerda, MA; Vianna, R | 1 |
| Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Müllhaupt, B; Rampini, SK; Schaffstein, S | 1 |
| Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M | 1 |
| Agarwal, K; Berg, T; Bernstein, B; Campbell, AL; Collins, CA; Da Silva-Tillmann, B; Forns, X; Hezode, C; Kowdley, KV; Lovell, SS; Podsadecki, T; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H; Yoshida, EM; Zeuzem, S | 1 |
| Barrero Alor, F; Casado Monge, PG; Jiménez Macías, FM; Pujol de la Llave, E; Ramos Lora, M; Ruíz-Frutos, C | 1 |
| Akahoshi, T; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Maehara, Y; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 1 |
| Bacon, BR; Bronowicki, JP; Bruno, S; Deng, W; DiNubile, MJ; Dutko, FJ; Esteban, R; Flamm, SL; Helmond, FA; Koury, KJ; Kwo, PY; Manns, MP; Pedicone, LD; Poordad, F; Vierling, JM; Wahl, J; Zeuzem, S | 1 |
| Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Pinilla, J; Plaza, Z; Soriano, V; Vispo, E | 1 |
| Grewal, P; Kim, B; Thung, SN; Trivedi, A | 1 |
| Chapman, R; Costella, A; De Angelis, D; Griffiths, J; Harris, HE; Harris, RJ; Ramsay, M; Thomas, B | 1 |
| Chan, J | 1 |
| Cao, GW; Lin, J; Wu, JF; Zhang, HW; Zhang, Q | 1 |
| Chen, TW; Chu, HC; Fan, HL; Hsieh, CB; Hsieh, TY; Hsu, KF | 1 |
| Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K | 1 |
| Abdurakmonov, D; Abrao Ferreira, P; Colombo, M; DeMasi, R; Fernández, I; Hill, A; Iraqi, W; Lonjon-Domanec, I; Moreno, C; Strasser, S; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H | 1 |
| Acero Fernández, D; Ferri Iglesias, MJ; Figa Francesch, M; Hombrados Verde, M; López Nuñez, C; Louvriex Freire, R; Virolés Torrent, S | 1 |
| Honda, M; Kaneko, S; Lemon, SM; Murai, K; Murakami, S; Okada, H; Sakai, Y; Shimakami, T; Shiomoto, T; Shirasaki, T; Takabatake, R; Tokumaru, A; Yamashita, T | 1 |
| Begovac, J | 1 |
| Colić-Cvrlje, V; Kanizaj, TF; Mrzljak, A; Ostojić, R | 1 |
| Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Rogalska-Taranta, M; Wedemeyer, H | 1 |
| Corchado, S; Girón-González, JA; López-Cortés, LF; Márquez-Coello, M; Rivero, A; Rivero-Juárez, A; Torres-Cornejo, A | 1 |
| Ahmed, A; Assem, N; Doss, W; El Kassas, M; El Raziky, M; Elsharkawy, A; Esmat, G; Hassany, M; Sabry, D | 1 |
| Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z | 1 |
| Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P | 1 |
| Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Soriano, V | 1 |
| Dan, YY; Elbasha, EH; Ferrante, SA; Hsu, TY | 1 |
| Arenas, JI; Bárcena, R; Buti, M; Calleja, JL; Crespo, J; de la Revilla, J; Delgado, M; Fernández-Rodríguez, CM; Forns, X; Gea, F; Larrubia, JR; Navarro, JM; Pascasio, JM; Pérez-Álvarez, R; Planas, R; Romero-Gómez, M; Ruiz-Antorán, B; Solá, R; Sousa, JM | 1 |
| Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Montes, M; Quereda, C; Santos, I; Sanz, J; Téllez, MJ; Von Wichmann, MA; Zamora, FX | 1 |
| Lutchman, GA; Nguyen, MH; Nguyen, NH; Vutien, P; Wong, CR; Yee, BE; Zhang, B | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J | 1 |
| Ahn, SH; Baatarkhuu, O; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Moon, C; Park, JY | 1 |
| Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA | 1 |
| Balart, LA; Behorquez, HE; Bohorquez, HE; Bruce, D; Carmody, I; Chandra, PK; Cohen, AJ; Dash, S; Gunduz, F; Hazari, S; Kurt, R; Loss, G; Panigrahi, R; Poat, B; Wu, T | 1 |
| Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA | 1 |
| An, D; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Poordad, F; Symonds, WT | 1 |
| Andrade, RJ; Buti, M; Casado, MA; Gros, B; Oyagüez, I; Serra, MA; Turnes, J | 1 |
| Chen, DS; Chen, PJ; Chung, CS; Kao, JH; Liang, CC; Lin, CK; Liu, CH; Liu, CJ; Su, TH; Yang, HC | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Cornberg, M; Höner zu Siederdissen, C | 1 |
| Charlton, MR; Gallegos-Orozco, JF | 1 |
| Feray, C; Hézode, C; Pawlotsky, JM; Ruiz, I | 1 |
| Arizumi, T; Hagiwara, S; Inoue, T; Kudo, M; Minami, T; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
| Bagaglio, S; Della Torre, L; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Uberti-Foppa, C | 1 |
| Aghemo, A; Donato, MF | 1 |
| Qi, W; Qin, S; Wang, J; Wang, X; Xu, Y; Zhang, Q; Zhang, Y; Zhao, P | 1 |
| Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J | 1 |
| Cornberg, M; Manns, MP | 1 |
| Aoki, Y; Hashimoto, S; Imamura, M; Izumi, N; Kage, M; Kang, JH; Kanto, T; Kimura, T; Korenaga, M; Kurosaki, M; Masaki, N; Mizokami, M; Murata, K; Naito, S; Nomura, H; Sugiyama, M; Takeda, T; Yamagiwa, Y; Yatsuhashi, H; Yoshio, S | 1 |
| Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S | 1 |
| Chan, J; Mohammad, RA; Smith, MA | 1 |
| Benanti, F; Cacopardo, B; D'Agata, V; Nunnari, G; Pinzone, MR; Rapisarda, L; Spartà, D; Zanghì, AM | 1 |
| Gattei, V; Mauro, E; Mazzaro, C | 1 |
| Ehleben, C; Pearlman, BL; Perrys, M | 1 |
| Andreone, P; Gamal, N; Vitale, G | 1 |
| Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Childs-Kean, LM; Hand, EO | 1 |
| Ahmed, A; Dieterich, D; Gordon, SC; Park, H; Saab, S; Younossi, ZM | 2 |
| Abraham, GM; Akushevich, L; Di Bisceglie, AM; El-Genaidi, H; Fenkel, JM; Fried, MW; Kuo, A; Mah'moud, MA; Nelson, DR; Rustgi, VK; Sterling, RK; Stewart, PW; Stewart, TG; Sulkowski, MS | 1 |
| Alric, L; Bailly, F; Bourlière, M; Bronowicki, JP; Carrat, F; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Loustaud-Ratti, V; Métivier, S; Pradat, P; Samuel, D; Serfaty, L; Virlogeux, V; Zarski, JP; Zoulim, F | 1 |
| Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA | 1 |
| Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L | 1 |
| Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX | 1 |
| Kim, AY; Naggie, S | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; Di Perri, G | 1 |
| Gale, SE; Klibanov, OM; Santevecchi, B | 1 |
| Adler, M; Bourgeois, S; Brixko, C; Deltenre, P; Delwaide, J; Henrion, J; Langlet, P; Moreno, C; Mulkay, JP; Nevens, F | 1 |
| Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K | 1 |
| Burnevich, EZ | 1 |
| Jäger-Becker, D | 1 |
| Abergel, A; Alric, L; Bourlière, M; Bronowicki, JP; de Ledinghen, V; Doehle, B; Grangé, JD; Guyader, D; Habersetzer, F; Hézode, C; Hyland, RH; Jiang, D; Larrey, DG; Leroy, V; Loustaud-Ratti, V; Marcellin, P; Mathurin, P; McHutchison, JG; Metivier, S; Pang, PS; Pol, S; Ratziu, V; Serfaty, L; Subramanian, GM; Symonds, WT; Tran, A; Zoulim, F | 1 |
| Afdhal, NH; Campbell, FM; Dusheiko, GM; Elkashab, M; Giannini, EG; Iyengar, M; Muir, AJ; Reddy, KR; Romero-Gómez, M; Sigal, SH; Theodore, D; Vasey, SY; Vijayaraghavan, S | 1 |
| Arena, U; Boldrini, B; Corti, G; Laffi, G; Marra, F; Milani, S; Montalto, P; Monti, M; Piluso, A; Salomoni, E; Stasi, C; Zignego, AL | 1 |
| Andriulli, A; Angelico, M; Di Marco, V; Fasano, M; Fattovich, G; Felder, M; Gaeta, GB; Gatti, P; Granata, R; Ippolito, AM; Mazzella, G; Milella, M; Morisco, F; Santantonio, T; Smedile, A; Valvano, MR | 1 |
| Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Maeda, Y; Maekita, T; Mori, Y; Moribata, K; Muraki, Y; Nuta, J; Shimizu, R; Shingaki, N; Takifuji, K; Tamai, H; Yamaue, H | 1 |
| Faisal, N; Lilly, LB; Marquez, M; Mumtaz, K; Renner, EL | 1 |
| Hirohashi, K; Kanazawa, A; Kubo, S; Tanaka, S; Uenishi, T; Yamamoto, T | 1 |
| Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC | 1 |
| Abd-Elaati, BM; Ehsan, NA; El-Araby, HA; Konsowa, HA; Sira, AM | 1 |
| Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S | 1 |
| Bañares, R; Berenguer, J; Catalina, MV; López, JC; Miralles, P; Pérez-Latorre, L; Rincón, D; Sánchez-Conde, M | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
| Chtioui, H; Decosterd, LA; Giostra, E; Majno, PE; Moradpour, D; Pascual, M; Vionnet, J | 1 |
| Chang, LC; Chen, LW; Chien, CH; Chien, RN; Hu, CC; Lin, CL; Liu, CJ | 1 |
| Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Ishiyama, K; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Naeshiro, N; Ochi, H; Ohdan, H; Tashiro, H; Tsuge, M | 1 |
| Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J | 1 |
| Colombo, M | 1 |
| Cooper, J; Dore, GJ; Everson, G; Freilich, B; Ghesquiere, W; Herring, R; Hézode, C; Hughes, EA; Kwo, P; Lalezari, J; McPhee, F; Muir, AJ; Pockros, PJ; Poordad, F; Ramji, A; Reau, N; Sheikh, A; Stuart, K; Swenson, ES; Thompson, AJ; Tran, A; Vierling, J; Yang, R; Yin, PD; Yozviak, J | 1 |
| Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S | 1 |
| Abdelatty, S; El Akel, W; El Raziky, M; Elsharkawy, A; Gamal Eldeen, H; Mabrouk, M; Said, SE; Tantawy, O | 1 |
| Bárcena, R; Berenguer, M; Buti, M; Calleja, JL; Crespo, J; Fernández, I; González, O; López, J; Pérez, F | 1 |
| Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD | 1 |
| Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B | 1 |
| Pár, A | 2 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Charlton, MR; Dhanasekaran, R; Mounajjed, T; Sanchez, W; Watt, KD; Wiesner, RH | 1 |
| Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Barcan, LA; Gadano, AC; Galdame, OA; Marciano, S | 1 |
| Aqel, BA; Chervenak, AE; Keaveny, AP; Leise, M; McLemore, R; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Bau, S; Busuttil, RW; Durazo, F; El Kabany, M; Goo, T; Han, S; Jimenez, M; Kaldas, F; Saab, S; Tong, MJ; Zhao, D | 1 |
| Ascione, A; Bruno, S; Coppola, C; Deodato, B; Mangia, A; Orlandini, A; Puoti, M; Schmitz, M | 1 |
| Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Fraenkel, L; Garcia-Tsao, G; Lim, J; Monto, A; Reyna, V | 1 |
| Anagnostopoulos, A; Aouri, M; Böni, J; Braun, DL; Decosterd, L; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Müllhaupt, B; Rauch, A; Weber, R | 1 |
| Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M | 1 |
| Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CJ; Tseng, TC | 1 |
| Bae, SH; Jang, ES; Jeong, SH; Jung, EU; Kim, IH; Kim, YS; Lee, HC; Lee, SS; Lee, YJ | 1 |
| Alexander, PC; James, AM; Long, AG; Shiffman, ML | 1 |
| Allam, S; Boursier, J; Bronowicki, JP; Canva, V; De Lédinghen, V; Ducancelle, A; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Moal, V; Poynard, T; Veillon, P; Vergniol, J; Zoulim, F | 1 |
| Gissel, C; Götz, G; Mahlich, J; Repp, H | 1 |
| Baskič, D; Djurdjevič, P; Jovanovič, D; Mijailovič, Z; Mitrovkič, S; Popovič, S; Vukovič, VR | 1 |
| Altus, R; Colman, A; Dan, YY; Fragomelli, V; Galhenage, S; Guan, R; Jones, T; Lee, YM; Leembruggen, N; Lim, SG; Luman, W; Mason, S; Mollison, L; Morales, B; Nazareth, S; Pham, T; Piratvisuth, T; Sendall, C; Sukeepaisarnjaroen, W; Sutedja, D; Tan, SS; Tanwandee, T; Teo, EK; Than, YM; Totten, L; Wigg, A | 1 |
| Antoni, C; Eisenbach, C; Galle, PR; Pathil, A; Schattenberg, JM; Sprinzl, MF; Stein, K; Steinebrunner, N; Stremmel, W; Wörns, MA; Zimmerer, T; Zimmermann, T | 1 |
| Agarwal, K; Barnes, E; Brainard, DM; Brown, A; Cooper, C; Forton, D; Foster, GR; George, J; Han, B; Lin, M; Massetto, B; McHutchison, JG; Nahass, RG; Pianko, S; Subramanian, GM | 1 |
| Berenguer, M; Everson, G; Ferenci, P; Forns, X; Fried, MW; Lopez-Talavera, JC; Lovell, S; Pedrosa, M; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H | 1 |
| Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D | 1 |
| Aerssens, J; Darling, JM; Fanning, G; Fried, MW; Johansson, S; Scholliers, A; Talloen, W; Tuefferd, M | 1 |
| Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J | 1 |
| Komolmit, P; Poovorawan, Y; Sukeepaisarnjaroen, W; Suksawatamnuay, S; Tangkijvanich, P; Thaimai, P; Thanapirom, K; Treeprasertsuk, S; Wasitthankasem, R | 1 |
| Brainard, DM; Clark, PJ; Estep, M; Hunt, S; McHutchison, JG; Negro, F; Patel, K; Paulson, M; Song, Q; Stamm, LM; Stepanova, M; Subramanian, GM; Younossi, ZM | 1 |
| Ahn, SH; Chon, YE; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Park, YN | 1 |
| Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J | 1 |
| Arai, M; Haga, Y; Imazeki, F; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Shirasawa, H; Yasui, S; Yokosuka, O | 1 |
| Farfour, E; Hillaire, S; Kahn, JE; Peytavin, G; Sené, T; Zucman, D | 1 |
| Asada, W; Hashimoto, S; Ichino, N; Kan, T; Kato, M; Kawabe, N; Kurashita, T; Murao, M; Nakano, T; Nakaoka, K; Nishikawa, T; Ohki, M; Osakabe, K; Shibata, A; Shimazaki, H; Sugiyama, H; Takagawa, Y; Takamura, T; Yoshioka, K | 1 |
| Augustyniak, K; Berak, H; Dobracka, B; Dobracki, W; Dudziak, M; Flisiak, R; Horban, A; Janczewska, E; Jurczyk, K; Kozielewicz, D; Kryczka, W; Lapinski, T; Librant-Suska, M; Lojewski, W; Musialik, J; Olszok, I; Pisula, A; Postawa-Klosińska, B; Ruszala, A; Wroblewski, J; Zarebska-Michaluk, D | 1 |
| Kozlov, VK; Nekrasova, AN; Stelmah, VV | 1 |
| Buti, M; Esteban, R | 1 |
| Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G | 1 |
| Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C | 1 |
| Bernstein, DE; Bourgeois, S; Elkhashab, M; Feld, JJ; Fu, B; Horsmans, Y; Howieson, K; Larsen, L; Moreno, C; Pangerl, A; Polepally, AR; Poordad, F; Reindollar, RW; Shulman, NS; Tam, E; Trinh, R; Younes, Z | 1 |
| Kwon, JH | 1 |
| Cai, Z; Dang, S; Deng, H; Guo, Y; Huang, N; Ji, F; Jia, X; Li, Z; Liu, L; Wang, Y; Xue, H; Zhang, S | 1 |
| Brainard, DM; Doehle, B; Dore, GJ; Flamm, SL; Gane, EJ; Han, L; Kumar, S; McHutchison, JG; McNally, J; Mogalian, E; Pianko, S; Rabinovitz, M; Reddy, KR; Roberts, SK; Shiffman, ML; Stedman, CA; Strasser, SI; Towner, WJ | 1 |
| Kattakuzhy, S; Kottilil, S; Tang, L; Ward, H; Wilson, E | 1 |
| An, D; Brainard, DM; Brown, RS; Bzowej, N; Charlton, M; Curry, MP; Doehle, B; Fenkel, JM; Flamm, SL; Fontana, R; Fried, M; Korenblat, KM; Lawitz, E; McHutchison, JG; McNally, J; Muir, AJ; O'Leary, JG; Osinusi, A; Reddy, KR; Schiano, T; Schiff, E; Teperman, L | 1 |
| Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawashima, A; Maeda, Y; Maekita, T; Mori, Y; Moribata, K; Niwa, T; Shingaki, N; Tamai, H | 1 |
| Aabakken, L; Dalgard, O; Grimstad, T; Isaksen, K; Karlsen, L; Sandvei, PK | 1 |
| Busuttil, RW; Cheng, EY; Holt, CD; Saab, S | 1 |
| Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S | 1 |
| Farnik, H; Herrmann, E; Lange, CM; Luhne, S; Sarrazin, C; Vermehren, J; Welker, MW; Welzel, T; Zeuzem, S | 1 |
| Abenavoli, L; Camera, S; Claar, E; Coppola, C; Coppola, N; De Luna, A; Federico, A; Gentile, I; Granata, R; Masarone, M; Morisco, F; Persico, M; Precone, D; Rosato, V; Salomone-Megna, A; Tartaglione, MT | 1 |
| Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y | 1 |
| Calvaruso, V; Craxì, A | 1 |
| Hézode, C | 2 |
| Boccaccio, V; Bruno, S; Maisonneuve, P; Russo, ML | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 1 |
| Nelson, DR; Peter, J | 1 |
| Serfaty, L | 1 |
| Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ | 1 |
| Arleo, A; Copetti, M; Mangia, A; Miscio, M; Piazzolla, V; Santoro, R; Squillante, MM | 1 |
| Angus, P; Bhore, R; Bronowicki, JP; Dore, GJ; Hezode, C; Jimenez-Exposito, MJ; Leroy, V; McPhee, F; Pianko, S; Pol, S; Stuart, K; Thompson, AJ; Tse, E | 1 |
| Cheng, N; Ford, R; Norvell, JP; Parekh, S; Pillai, AA; Spivey, JR; Wedd, J; Young, N | 1 |
| Brainard, DM; Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Han, L; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mathias, A; Mo, H; Peng, CY; Sheen, IS; Wang, HY; Yang, JC | 1 |
| Aldamiz-Echevarria, T; Benito, JM; Berenguer, J; Carrero, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Restrepo, C; Soriano, V; Vazquez-Morón, S | 1 |
| Brennan, BJ; Eng, S; Gane, EJ; Hassanein, T; Kupcova, V; Le Pogam, S; Mazur, W; Morcos, PN; Rouzier, R; Scalori, A; Stedman, CA; Thommes, J; Voulgari, A | 1 |
| Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O | 1 |
| Afdhal, N; Charlton, M; Denning, J; Everson, GT; Flamm, SL; Hyland, R; Lin, M; McHutchison, JG; Pang, PS; Reddy, KR; Welzel, TM; Zeuzem, S | 1 |
| Agarwal, K; Angus, P; Arterburn, S; Brainard, D; Buti, M; Calleja, JL; Colombo, M; Denning, J; Dufour, JF; Dvory-Sobol, H; Forns, X; Gane, EJ; Manns, M; McCaughan, G; McHutchison, JG; Müllhaupt, B; Mutimer, D; Pang, PS; Peck-Radosavljevic, M; Prieto, M; Rizzetto, M; Samuel, D; van Hoek, B; Van Vlierberghe, H; Yoshida, EM | 1 |
| Barve, A; Brock, G; Buchanan, LA; Cave, B; Cave, MC; Crittenden, NE; Davis, EG; Gedaly, R; Jones, CM; Kuns-Adkins, CB; Marsano, L; Marvin, MR; McClain, CJ; Pinkston, CM; Rosenau, J; Shah, MB | 1 |
| Gonzalez, HC; Nair, S; Satapathy, SK | 1 |
| Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P | 1 |
| Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N | 1 |
| Cooper, C; Gill, J; Hull, M; Klein, MB; Moqueet, N; Platt, RW | 1 |
| Brennan, BJ; Hill, G; Kao, JH; Le Pogam, S; Lee, Y; Li, H; Najera, I; Sheen, IS; Tanwandee, T; Thommes, JA; Thongsawat, S; Tung, SY; Wu, JJ; Zhou, J | 1 |
| Kim, KA | 1 |
| Gwak, GY | 1 |
| Bronte, F; Calvaruso, V; D'Ambrosio, R; Di Marco, V; Forni, G; Lanza, AG; Poggiali, E; Saracco, G | 1 |
| Arini, A; Bavetta, MG; Cabibbo, G; Calvaruso, V; Cammà, C; Conte, E; Craxì, A; Di Marco, V; Ferraro, D; Grimaudo, S; Peralta, S; Pipitone, RM; Simone, F | 1 |
| Banerjee, D; Reddy, KR | 1 |
| Cannizzaro, M; Cottone, M; Madonia, G; Madonia, S; Orlando, E; Stagno, B | 1 |
| Diago, M; Peño, L; Plana, L; Urquijo, JJ | 1 |
| Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF | 1 |
| Herbst, H; Ingiliz, P; Mayr, C; Obermeier, M; Pischke, S; Polywka, S | 1 |
| Anand, BS; Aytaman, A; Brau, N; Chang, KM; Cheung, R; Cozen, ML; Kaplan, DE; Monto, A; Morgan, T; Pedrosa, M; Pocha, C; Ryan, JC; Schmidt, WN; Shen, H | 1 |
| Warpakowski, A | 1 |
| Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA | 1 |
| Choi, HS; Chun, HJ; Jung, CH; Kim, TH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY | 1 |
| Goto, H; Hayashi, K; Hirai, T; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Tachi, Y | 1 |
| Bulja, D; Husic-Selimovic, A; Huskic, J; Sofic, A | 1 |
| Ivanova, AL; Tarasova, LV | 1 |
| Abdel-Hamid, NM; Eisa, MA; Nazmy, MH; Wahid, A | 1 |
| Cammà, C; Damele, F; Marcellusi, A; Mennini, FS; Taliani, G; Viti, R | 1 |
| Brainard, DM; Byrne, S; Copans, A; Dvory-Sobol, H; Fuchs, M; Guyer, W; Ho, SB; Kaplan, DE; Le, H; Monto, A; Moon, S; Morgan, TR; Peyton, A; Rossaro, L; Roy, A; Shaikh, O; Zhu, Y | 1 |
| Acharya, SK; Das, P; Gupta, SD; Kalra, N; Kavimandan, A; Nayak, B; Panda, SK; Thakur, B; Vasudevan, S | 1 |
| Almeida, PR; Barros, IC; Casagrande, L; Dresch, KF; Feltrin, AA; Mattos, AA; Onofrio, FQ; Tovo, CV | 1 |
| Flemming, JA; Lowe, CE | 1 |
| Alric, L; Aumaître, H; Bani-Sadr, F; Billaud, E; Bouchaud, O; Boué, F; Chas, J; Dabis, F; Dominguez, S; Esterle, L; Gervais, A; Gilbert, C; Goujard, C; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Morlat, P; Neau, D; Piroth, L; Poizot-Martin, I; Rosenthal, E; Salmon, D; Simon, A; Sogni, P; Valantin, MA; Vittecoq, D; Wittkop, L; Zucman, D | 1 |
| Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E | 1 |
| Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Amoroso, A; Arese, D; Cocchis, D; Dell Olio, D; Magistroni, P; Martini, S; Mirabella, S; Moschini, P; Ottobrelli, A; Rizza, G; Rizzetto, M; Romagnoli, R; Sacco, M; Salizzoni, M; Saracco, GM; Stradella, D; Strona, S; Tandoi, F | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A | 1 |
| Alem, SA; Asem, N; El-Sayed, M; Elsharkawy, A; Esmat, G; Fouad, R; Hassan, E; Ismail, A; Yosry, A | 1 |
| Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R | 1 |
| Ceccherini-Silberstein, F; Craxì, A; Perno, CF; Petta, S; Viganò, M | 1 |
| Agarwal, K; Brown, A; Cheung, MCM; Foster, GR; Gelson, WTH; Hudson, BE; Irving, WL; MacDonald, DC; McLauchlan, J; Mutimer, DJ; Verma, S; Walker, AJ | 1 |
| Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME | 1 |
| Bajaj, JS; Betrapally, NS; Daita, K; Fuchs, M; Ganapathy, D; Gillevet, PM; Heuman, DM; Hylemon, PB; Nixon, DE; Sikaroodi, M; Sterling, RK; White, MB | 1 |
| Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S | 1 |
| Buggisch, P; Cornberg, M; Günther, R; John, C; Klinker, H; Lutz, T; Mauss, S; Niederau, C; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Tacke, F | 1 |
| Castelli, F; Di Filippo, E; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Gagliardini, R; Gori, A; Maggiolo, F; Pan, A; Postorino, MC; Prosperi, M; Quiros Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
| Chen, GF; Chen, J; Hu, JH; Ji, D; Lau, G; Li, B; Liu, JL; Lu, L; Niu, XX; Shao, Q; Wang, C; Wang, YD; Wu, V; You, SL; Zhao, J | 1 |
| Aba Alkhail, F; Ajlan, A; Al-Hamoudi, W; Al-Jedai, A; Al-Sebayel, M; Alarieh, R; Alkortas, D; Broering, D; Elsiesy, H | 1 |
| Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K | 1 |
| Butt, AA; Marks, K; Shaikh, OS; Sherman, KE; Yan, P | 1 |
| Choi, JW; Hong, SH; Jang, JW; Kim, DY; Kim, I; Kim, W; Lee, D; Lee, JI; Paik, YH; Yoon, KT | 1 |
| Etschmaier, A; Ferenci, P; Ferlitsch, A; Ferlitsch, M; Hametner, S; Hofer, H; Horvatits, T; Maieron, A; Paternostro, R; Peck-Radosavljevic, M; Quehenberger, P; Reiberger, T; Rutter, K; Salzl, P; Trauner, M | 1 |
| Afdhal, NH; Buti, M; Curry, MP; Dufour, JF; Firdoos, S; Flamm, S; Hughes, MS; Tapper, EB | 1 |
| Bailly, F; Choupeaux, L; Gagnieu, MC; Maynard, M; Pradat, P; Scholtès, C; Virlogeux, V; Zoulim, F | 1 |
| Kukhareva, EI; Ogurtsov, PP | 1 |
| Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Ng, KJ; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF | 1 |
| Keating, GM | 1 |
| Aspinall, RJ; Brainard, DM; Dore, GJ; Feld, JJ; Foster, GR; Fox, R; Grebely, J; Han, L; Mangia, A; McNally, J; Natha, M; Osinusi, A; Subramanian, GM; Sulkowski, M; Zeuzem, S | 1 |
| Alric, L; Anty, R; Beaulieux, F; Botta-Fridlund, D; Bouix, C; Canva, V; Carrieri, MP; Conti, F; D'Alteroche, L; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fontaine, H; Lebray, P; Leroy, V; Maynard, M; Métivier, S; Pageaux, GP; Paul, C; Petrov-Sanchez, V; Pradat, P; Roche, B; Roque-Afonso, AM; Samuel, D; Vilotitch, A; Wellems, C | 1 |
| Akushevich, L; Ben Ari, Z; Di Bisceglie, AM; Frazier, LM; Fried, MW; Kuo, A; Lim, JK; Lok, AS; Nelson, DR; Pockros, PJ; Shiffman, ML; Sulkowski, MS; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Boo, SJ; Cho, YK; Choi, EK; Jeong, SU; Kim, BS; Kim, HU; Lee, SJ; Na, SY; Song, BC; Song, HJ | 1 |
| Drago, F; Gasparini, G; Marenco, S; Parodi, A; Picciotto, A | 1 |
| Bae, SH; Cho, SB; Jang, ES; Jeong, SH; Kim, IH; Kim, YS; Lee, HC; Lee, YJ; Ok, KS | 1 |
| Arns, CW; Bastos, JC; Caserta, LC; Miotto, N; Padilla, MA; Vigani, AG | 1 |
| Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D | 1 |
| Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X | 1 |
| Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B | 1 |
| Fortune, BE; Lim, JK; McCarty, TR; Njei, B | 1 |
| Kwo, PY; Liangpunsakul, S | 1 |
| Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Greig, SL | 1 |
| Brooks-Rooney, C; Dan, YY; Eguchi, Y; Kawada, N; Lim, YS; Mondelli, MU; Negro, F; Tanaka, A; Younossi, ZM; Yu, ML | 1 |
| Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Akuschevich, L; Brown, RS; Di Bisceglie, AM; Everson, GT; Fried, MW; Galati, JS; Kuo, A; Kwo, PY; Lim, JK; Lok, AS; Manns, MP; Morelli, G; Nelson, DR; Pockros, PJ; Reddy, KR; Sulkowski, MS; Terrault, NA; Vainorius, M | 1 |
| Charlton, M; Curry, MP; Feld, J; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; O'Leary, JG; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S | 1 |
| Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R | 1 |
| But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF | 1 |
| Kahn, JG; Lai, JC; Mehta, N; Roberts, JP; Salazar, J; Saxena, V; Volk, M | 1 |
| Liu, H; Yan, Y; Zhang, T | 1 |
| Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M | 1 |
| Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J | 1 |
| De Stafano, V; Guo, X; Qi, X | 1 |
| Kumar, P; Singh, V; Taneja, S | 1 |
| Belli, LS; Perricone, G; Vangeli, M | 1 |
| Agostinacchio, E; Arleo, A; Carraturo, I; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Miscio, M; Palmieri, V; Piazzolla, V; Potenza, D; Santoro, R; Sarrazin, C; Spinzi, G; Susser, S | 1 |
| Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S | 1 |
| Alberti, A; Bonfanti, M; Croce, D; Lazzarin, A; Nappi, C; Restelli, U | 1 |
| Bai, X; Calleja, JL; Forns, X; Garcia-Samaniego, J; Kaste, R; Manns, M; Sarrazin, C; Stern, JO; Wu, J | 1 |
| Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH | 1 |
| Chen, Y; Jiang, X; Song, Y; Tao, T | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J | 1 |
| Lange, CM; Mücke, MM; Mücke, VT; Zeuzem, S | 1 |
| Bucher, HC; Calleja, JL; Castells, L; Evans, D; Giostra, E; Hofer, H; Irving, W; Lefevre, C; Pascasio, JM; Postema, R; Prieto, M; Weiland, O; Weis, N; Young, J | 1 |
| Jin, YJ; Lee, JW; Lee, SH; Shin, JY | 1 |
| Aherfi, S; Brouqui, P; Colson, P; Dhiver, C; Meddeb, L; Menard, A; Mokhtari, S; Ravaux, I; Stein, A; Tissot-Dupont, H | 1 |
| Berg, T; Böker, KH; Cornberg, M; Günther, R; Hüppe, D; Link, R; Manns, MP; Mauss, S; Niederau, C; Petersen, J; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Serfert, Y | 1 |
| Baldanti, F; Ludovisi, S; Mondelli, MU; Paolucci, S; Premoli, M | 1 |
| Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T | 1 |
| Kumakawa, M; Matsumoto, N; Matsumura, H; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamagami, H | 1 |
| Ascione, T; Borgia, G; Buonomo, AR; Calò, F; Coppola, N; De Pascalis, S; de Stefano, G; Di Caprio, G; Federico, A; Filippini, P; Gaeta, GB; Gentile, I; Martini, S; Messina, V; Minichini, C; Persico, M; Rinaldi, L; Sangiovanni, V; Stanzione, M; Starace, M; Stornaiuolo, G; Zampino, R | 1 |
| Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J | 1 |
| Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F | 1 |
| Li, CX; Li, W; Li, ZQ; Liang, HX; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, JY | 1 |
| Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J | 1 |
| Lim, SG | 1 |
| Cai, QX; Chen, YM; Gao, ZL; Lin, CS; Zhang, GL; Zhang, T; Zhang, XH; Zhao, ZX | 1 |
| Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C | 1 |
| Almarzooqi, S; Emery, JS; Feld, JJ; Janssen, HLA; Kowgier, M; Kuczynski, M; La, D; Shah, H; Wong, D | 1 |
| Kaden, T; Niederau, C | 1 |
| Akue-Goeh, P; Howaizi, M; Maurer-Chagrin, F | 1 |
| Anselmo, M; De Leo, P; Grasso, A; Malfatti, F; Menardo, G; Toscanini, F | 1 |
| Aleman, S; Birk, M; Carlsson, T; Davidsdottir, L; Hagen, K; Hultcrantz, R; Oksanen, A; Rahbin, N; Syed, E; Weiland, O | 1 |
| Burroughs, A; Calvaruso, V; Corbani, A; Leandro, G; Manousou, P; Patch, D; Sigalas, A; Triantos, C; Xirouchakis, E | 1 |
| Eason, J; Lipscomb, J; Nair, S | 1 |
| Bärthel, E; Habrecht, O; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
| Bellati, G; Bellia, V; Bruno, S; Ceriani, R; Colloredo, G; Corradi, C; Del Poggio, P; Fornaciari, G; Parravicini, P; Pioltelli, P; Pozzpi, M; Ramella, G; Roffi, L; Rossini, A | 1 |
| Blanco, Cdel V; Federico, A; Loguercio, C; Masarone, M; Persico, M; Torella, R | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Dev, AT; Heller, K; Kauf, TL; McHutchison, JG; Patel, K; Schulman, KA; Zekry, A | 1 |
| Alsiö, A; Dhillon, AP; Ferrari, C; Hellstrand, K; Islam, S; Lagging, M; Neumann, AU; Pawlotsky, JM; Schalm, SW; Westin, J; Ydreborg, M; Zeuzem, S | 1 |
| Brinkmann, K; Sabranski, M; Stoehr, A | 1 |
| Antonini, T; Canfora, ML; Castaing, D; Delvart, V; Duclos-Vallee, JC; Roche, B; Roque-Afonso, AM; Saliba, F; Samuel, D; Sebagh, M | 1 |
| Andriulli, A; Iacobellis, A; Ippolito, A | 1 |
| Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Lok, AS; Naishadham, D; Sterling, RK; Su, GL | 1 |
| Pozza, R | 1 |
| Benanti, F; Cacopardo, B; Caltabiano, E; Cappellani, A; Nunnari, G; Onorante, A; Russo, R | 1 |
| Elgouhari, HM; Feldstein, AE; Hanouneh, I; Zein, CO; Zein, NN | 1 |
| Benhamou, Y; Kaita, KD; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Torbenson, M; Yoshida, EM; Zeuzem, S | 1 |
| Bernard, PH; Castéra, L; Chanteloup, E; Couzigou, P; de Lédinghen, V; Foucher, J; Merrouche, W; Terrebonne, E; Tournan, R; Vergniol, J | 1 |
| Fiel, MI; Schiano, T | 1 |
| Aberle, JH; Gangl, A; Holzmann, H; Kohrgruber, N; Kundi, M; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K | 1 |
| Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Hoefs, JC; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Sterling, RK | 1 |
| Fujita, N; Hara, N; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Miyachi, H; Takei, Y; Takeo, M; Tanaka, H | 1 |
| Bailey, RJ; Bain, VG; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, K; Sherman, M; Usaty, C; Witt-Sullivan, H; Yoshida, EM | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Hsu, CS; Kao, JH; Lai, MY; Liu, CH; Liu, CJ | 1 |
| Ghany, MG; Seeff, LB; Strader, DB; Thomas, DL | 1 |
| Chuang, WL; Yu, ML | 1 |
| Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I | 1 |
| Pol, S | 3 |
| Agoglia, L; Balbi, E; Cariús, LP; Covelo, MC; Enne, M; Gonzalez, AC; Leal, CR; Oliveira, PV; Pacheco-Moreira, LF; Pousa, FS; Roma, J | 1 |
| Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Niro, GA; Siciliano, M; Valvano, MR | 1 |
| Asjø, B; Myrmel, H; Ulvestad, E | 1 |
| Bédossa, P; Cacoub, P; Carrat, F; Halfon, P; Lambert, J; Pénaranda, G; Perronne, C; Pol, S | 1 |
| Bashirova, A; Bonkovsky, HL; Carrington, M; Chanock, SJ; Chung, RT; Crenshaw, AT; Di Bisceglie, AM; Dotrang, M; Fontana, RJ; Ghany, MG; Gretch, DR; Hutchinson, AA; Lee, WM; Lindsay, KL; Morgan, TR; Naishadham, D; O'Brien, TR; Pfeiffer, RM; Sterling, RK; Welzel, TM; Wright, EC | 1 |
| Furusyo, N; Hayashi, J; Maeda, S; Ogawa, E; Takeoka, H; Toyoda, K | 1 |
| Coffin, CS; Terrault, NA | 1 |
| Berg, T; Biermer, M | 1 |
| Armendáriz-Borunda, J; Bautista López, CA; Lugo-Baruqui, A | 1 |
| Andriulli, A; Iacobellis, A | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Donato, MF; Monico, S; Prati, GM; Rumi, MG | 1 |
| Alvarez-Uria, G; Day, JN; Nasir, AJ; Russell, SK; Vilar, FJ | 1 |
| Coppola, N; Iodice, V; Macera, M; Piccinino, F; Sagnelli, E; Stanzione, M; Tonsiello, G | 1 |
| Berenguer, J; Girón, JA; González-Serrano, M; Iribarren, JA; Japón, MA; López-Cortés, LF; Macías, J; Mira, JA; Miralles, P; Moreno, A; Ortega, E; Pineda, JA; Rivero, A | 1 |
| Bedossa, P; Boyer, N; Cardoso, AC; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Nicolas-Chanoine, MH; Ripault, MP; Stern, C; Valla, D; Vidaud, M; Voitot, H | 1 |
| Akahoshi, T; Ikejiri, K; Korenaga, D; Saku, M; Takenaka, K; Tomikawa, M | 1 |
| Bach, N; Chang, C; Elsiesy, H; Grewal, P; Khaitova, V; Liu, L; Massoumi, H; Norkus, E; Peterson, B; Schiano, TD | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Naishadham, D; Shiffman, ML; Wright, EC | 1 |
| Ha, CY; Ju, K; Jung, WT; Kim, TH; Lee, OJ; Min, HJ; Shin, MK | 1 |
| Almerighi, C; Angelico, M; Anselmo, A; De Luca, L; Lenci, I; Lionetti, R; Monaco, A; Palmieri, G; Tariciotti, L; Tisone, G | 1 |
| Basso, M; Giannini, EG; Picciotto, A; Savarino, V | 1 |
| Wei, L | 1 |
| Bruno, S; Gane, EJ; Hadziyannis, SJ; Marcellin, P; Messinger, D; Roberts, SK; Shiffman, ML | 1 |
| Chen, SC; Chu, PY; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, YY; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Maida, I; Martin-Carbonero, L; Soriano, V; Sotgiu, G; Vispo, E | 1 |
| Bono, A; Cabibi, D; Cammà, C; Craxí, A; Di Marco, V; Licata, G; Marchesini, G; Petta, S; Porcasi, R; Scazzone, C; Tripodo, C | 1 |
| Bielawski, KP; Izycka-Swieszewska, E; Romanowski, T; Sikorska, K; Stalke, P | 1 |
| Hagen, K; Rosenberg, P | 1 |
| Begovac, J; Romih, V | 1 |
| Galdame, O; Jorge, A; Sordá, J | 1 |
| Nilsson, J; Weiland, O | 1 |
| Bruix, J; Forns, X | 1 |
| Bruggmann, P; Dampz, M; Falcato, L; Gerlach, T; Kravecz, L | 1 |
| Cheong, HR; Cho, M; Heo, J; Kang, DH; Kim, DU; Kim, GH; Song, GA; Woo, HY; Yoon, KT | 1 |
| Benito, JM; Goldstein, D; McHutchison, J; Medrano, J; Naggie, S; Rallón, NI; Restrepo, C; Shianna, KV; Soriano, V; Thompson, A; Vispo, E | 1 |
| Balart, LA; Hamzeh, FM; Kwok, A; Lentz, E; Lisker-Melman, M; Rodriguez-Torres, M | 1 |
| Cross, TJ; Harrison, PM; Hughes, S; Nolan, J; Quaglia, A | 1 |
| Alonso, N; Martínez-Arconada, MJ; Martínez-Cáceres, EM; Morillas, RM; Planas, R; Sanmartí, AM; Soldevila, B | 1 |
| Arnholm, B; Buhl, MR; Eilard, A; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Mørch, K; Nilsson, S; Norkrans, G; Pedersen, C; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Berenguer, M; Rubin, A | 1 |
| Hunt, DR; McClune, A; Saab, S; Stone, MA; Tong, MJ | 1 |
| Sherman, KE | 1 |
| Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tung, WC; Wang, JH | 1 |
| Adams, LA; Bulsara, M; Cheng, W; Flexman, JP; Lee, S; Price, P; Rossi, E; Varano, J; Watson, MW | 1 |
| Carvalho Filho, RJ; Ferrari, MV; Ferraz, ML; Freire, FC; Narciso-Schiavon, JL; Scanhola, GQ; Schiavon, Lde L; Silva, AE; Suarez, MM | 1 |
| Gómez-Domínguez, E; González-Moreno, L; Jones, EA; Mendoza, J; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Cheng, WS; Crawford, D; Dore, GJ; Marks, PS; McCaughan, G; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Thommes, J; Weltman, M; Yoshihara, M | 1 |
| Fowell, AJ; Nash, KL | 1 |
| Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Goodman, ZD; Lok, AS; Naishadham, D; Sterling, RK; Su, GL; Wright, EC | 1 |
| Alonso, S; Bárcena, R; Fernandez, I; Fernández-Rodríguez, CM; Forns, X; Fuente, J; Garcia-Samaniego, J; Martinez, SM; Moreno-Otero, R; Planas, R; Rincón, D; Rodriguez-Caravaca, G; Romero-Gómez, M; Sanchez-Tapias, JM; Serra, MA; Solá, R | 1 |
| Daruich, J | 1 |
| Zapata, R | 1 |
| Bakulin, IG; Sharabanov, AS | 1 |
| Kaur, A; Mehta, V; Midha, V; Mittal, R; Sharma, S; Sood, A; Sood, N; Thara, A | 1 |
| Barreiro, P; González-Lahoz, J; Labarga, P; Martín-Carbonero, L; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Eguchi, K; Eguchi, S; Hayashi, T; Ichikawa, T; Ida, H; Iwamoto, N; Kanematsu, T; Kawakami, A; Matsuzaki, T; Miyaaki, H; Nakamura, H; Nakamura, T; Nakao, K; Yamasaki, S | 1 |
| Fukuhara, T; Gion, T; Ikegami, T; Maehara, Y; Morita, K; Nagata, S; Soejima, Y; Sugimachi, K; Takeishi, K; Taketomi, A; Toshima, T; Umeda, K | 1 |
| Alston, B; Andersen, JW; Butt, AA; Chung, RT; Goodman, ZD; Koziel, MJ; Peters, MG; Sherman, KE; Sulkowski, M; Umbleja, T | 1 |
| Bota, S; Curescu, M; Gheorghe, L; Iacob, S; Popescu, A; Sirli, R; Sporea, I | 1 |
| Ghany, MG; Noureddin, M | 1 |
| Ghany, MG; Seeff, LB | 1 |
| Albrecht, J; Berg, T; Boparai, N; Brass, C; Bruix, J; Burroughs, M; Carrilho, F; Colombo, M; Craxi, A; Diago, M; Flamm, S; Gonçales, F; Griffel, L; Heathcote, EJ; McGarrity, T; Moreno-Otero, R; Munteanu, M; Poynard, T; Schiff, E; Schmidt, W; Silva, M; Terg, R | 1 |
| Andersen, ES; Christensen, PB; Kjær, M; Krarup, H; Lillevang, S; Moessner, BK; Weis, N | 1 |
| Bruguera, M; Fernández-Varo, G; Forns, X; González, P; Jiménez, W; Martinez, SM; Navasa, M; Sampson, E; Sánchez-Tapias, JM | 1 |
| Bahgat, MM; El-Gammal, NE; Emara, MH; Mohamed, LA | 1 |
| Andriulli, A; Caruso, N; Iacobellis, A; Niro, GA; Perri, F; Valvano, MR | 1 |
| Al Dweik, NZ; Alkaabi, SR; Almohanadi, M; Amer, AM; Amin, A; Butt, MT; Derbala, MF; John, A; Pasic, F; Sharma, M; Shebl, FM; Yaqoob, R | 1 |
| Lawson, A | 1 |
| Antonino, AT; Bechstein, WO; Bibert, S; Bochud, PY; Doehring, A; Farnik, H; Hansmann, ML; Hofmann, WP; Lange, CM; Lehr, HA; Lötsch, J; Moench, C; Moradpour, D; Müllhaupt, B; Pascual, M; Sarrazin, C; Shi, Y; Zeuzem, S | 1 |
| Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N | 1 |
| Ferguson, MC | 1 |
| Abdalla, MS; Abdalla, S; Anany, MA; Bader El Din, NG; El Akel, W; El Awady, MK; El Raziky, M; El Zayady, AR; Esmat, G; Helmy, A; Sharada, HM; Tabll, AA; Zayed, N | 1 |
| Gonzalez, SA | 1 |
| Fujise, K; Namiki, Y; Tada, N; Tsubota, A | 1 |
| Berenguer, J; Carrero-Gras, A; Catalán, P; Cosín, J; García-Álvarez, M; Guzmán-Fulgencio, M; López, JC; Micheloud, D; Miralles, P; Resino, S | 1 |
| Aoyagi, Y; Ikeda, H; Matsuda, Y; Morita, S; Nomoto, M; Ohkoshi, S; Takahashi, H; Takeuchi, M; Tanaka, Y; Yamagiwa, S; Yano, M | 1 |
| Aghemo, A; Colombo, M; Vezali, E | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Cacoub, P; Carrat, F; Geri, G; Halfon, P; Piroth, L; Pol, S; Poynard, T; Souberbielle, JC; Terrier, B | 1 |
| Hama, T; Hayami, S; Ichinose, M; Shigekawa, Y; Takifuji, K; Tamai, H; Uchiyama, K; Ueno, M; Yamaue, H | 1 |
| Casas Rodrigo, M; Cebollero Agustí, A; Dalmau Obrador, B; Gallach Montero, M; Gavarró Puig, A; Gil Prades, M; Miquel Planas, M; Puig Del Castillo, I; Sánchez Delgado, J; Tomás Tutusaus, R; Vergara Gómez, M | 1 |
| Glória, H; Marinho, R; Nunes, J; Serejo, F; Velosa, J | 1 |
| Curto, TM; Everhart, JE; Freedman, ND; Lindsay, KL; Sinha, R; Wright, EC | 1 |
| Eslam, M; Maraver, M; Romero-Gomez, M; Ruiz, A | 1 |
| Biesiada, G; Dumnicka, P; Kuśnierz-Cabala, B; Mach, T; Solnica, B | 1 |
| Beinhardt, S; Ferenci, P; Ferlitsch, A; Gangl, A; Hofer, H; Kundi, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Trauner, M | 1 |
| Cacoub, P; Resche-Rigon, M; Saadoun, D; Semoun, O; Sène, D; Terrier, B | 1 |
| Abdurakhmanov, DT; Baĭzhanova, ZhZh; Ignatova, TM; Nekrasova, TP | 1 |
| Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Noguchi, R; Shirai, Y; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Honda, M; Kaneko, S; Lemon, SM; Mizukoshi, E; Muramatsu, T; Nakamoto, Y; Nakamura, M; Nishitani, S; Sakai, A; Sakai, Y; Shimakami, T; Shirasaki, T; Suzuki, T; Tagata, Y; Takehana, K; Wakita, T; Yamashita, T; Yi, M | 1 |
| Chang, SW; Chen, JY; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Lin, TN; Sheen, IS | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Lee, WM; Morgan, TR; Morishima, C; Seeff, LB; Shiffman, ML; Snow, KK; Stoddard, AM; Wright, EC | 1 |
| Husa, P; Ivanovski, L; Messinger, D; Oltman, M; Rehák, V; Tietz, A; Urbanek, P | 1 |
| Benito, JM; Goldstein, D; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E | 1 |
| Bae, SH; Choi, JY; Jeong, SW; Kim, JD; Kwon, JH; Lee, JE; Song, MJ; Yoon, NR; Yoon, SK | 1 |
| Garcia, GF; Garib, JR; Silva, Fd; Teixeira, R | 1 |
| Abdullah, NA; Amr, KS; El-Batae, HE; Elhosary, YA; Ezzat, WM; Raslan, HM | 1 |
| Masarone, M; Persico, M | 1 |
| Brown, A; Foster, GR; Freshwater, D; Marley, R; Moreea, S; Mutimer, D; Rowe, IA; Sabin, CA; Shoeb, D; Sood, R | 1 |
| Crouzet, J; Di Martino, V; Hillon, P; Minello, A; Monnet, E; Thévenot, T | 1 |
| Rosen, HR | 1 |
| Dienstag, JL; Goodman, ZD; Hoefs, JC; Kleiner, DE; Shiffman, ML; Stoddard, AM | 1 |
| Chawla, YK; Das, A; Dhiman, RK; Duseja, A; Ghosh, S; Sharma, BK; Taneja, S; Tohra, SK | 1 |
| Akbal, E; Koçak, E; Köklü, S; Taş, A | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Toyoda, H; Yoshioka, K | 1 |
| Bouvier-Alias, M; Castéra, L; Hézode, C; Leroy, V; Mallat, A; Pawlotsky, JM; Rosa, I; Roudot-Thoraval, F; Roulot, D | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Donato, MF; Prati, GM; Rumi, MG | 1 |
| Aguilera, V; Berenguer, M; Giusto, M; López-Andujar, R; Navarro, L; Ortiz, C; Prieto, M; Rodriguez, M; Rubin, A; San-Juan, F | 1 |
| Corouge, M; Pol, S | 1 |
| Akahoshi, T; Furusyo, N; Hashizume, M; Hayashi, J; Kawanaka, H; Kinjo, N; Maehara, Y; Nagao, Y; Tomikawa, M; Tsutsumi, N | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; de Franchis, R; De Nicola, S; Dell'Era, A; Donato, MF; Lampertico, P; Prati, GM; Primignani, M; Rumi, MG | 1 |
| Arai, M; Fujiwara, K; Fukai, K; Imazeki, F; Kanda, T; Kato, K; Kimura, M; Mikami, S; Miyauchi, T; Nishino, T; Shimada, N; Sugiura, N; Takada, N; Takashi, M; Tsubota, A; Yokosuka, O; Yonemitsu, Y | 1 |
| Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M | 1 |
| Bota, S; Danila, M; Neghina, AM; Popescu, A; Sirli, R; Sporea, I; Strain, M | 1 |
| Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH | 1 |
| Shouval, D | 1 |
| Curto, TM; Everson, GT; Hoefs, JC; Lauriski, S; Morgan, TR; Shiffman, ML; Sterling, RK; Stoddard, A; Wagner, DA; Wright, EC | 1 |
| Bibert, S; Bochud, PY; Cerny, A; Dollenmaier, G; Dufour, JF; Gerlach, TJ; Heim, MH; Kutalik, Z; Lange, CM; Malinverni, R; Moradpour, D; Morikawa, K; Müllhaupt, B; Negro, F | 1 |
| Asselah, T; Bedossa, P; Laouénan, C; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Nicolas-Chanoine, MH; Panhard, X | 1 |
| Chung, WJ; Hwang, JS; Jang, BK; Kim, KH; Kweon, YO; Lee, CH; Lee, HJ; Suh, JI; Tak, WY | 1 |
| Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Litman, HJ; Lok, AS; Sterling, RK; Su, G | 1 |
| Ando, K; Fujinami, A; Fukuda, K; Hasegawa, Y; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Komaki, T; Kudo, M; Maekawa, Y; Nagata, Y; Nakajima, T; Ohta, M; Ohtani, A; Otono, Y; Saito, J; Sugimoto, K | 1 |
| Lim, JK; Porto, AF; Tormey, L | 1 |
| Golik, OO; Konstantinov, DIu; Popova, LL; Suzdal'tsev, AA; Vasil'ev, SIu | 1 |
| Goulis, I; Karatapanis, S; Ketikoglou, I; Lisgos, P; Papastergiou, V; Saitis, I; Skorda, L; Stampori, M; Tsitsopoulos, E; Tsoplou, P; Vasiageorgi, A | 1 |
| Croner, R; Demir, R; Hohenberger, W; Müller, V; Perrakis, A; Schellerer, V; Schuhmann, S; Yedibela, S | 1 |
| Febles, MH; Hernández, LO; López, MJ; Martínez, ER; Román, JL; Sánchez, CG; Suárez, JM; Vanegas, NO | 1 |
| Kwo, PY | 1 |
| Lin, F; Reddy, KR; Zoulim, F | 1 |
| Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C | 1 |
| Roche, B; Samuel, D | 1 |
| Mangia, A; Mottola, L | 1 |
| El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M | 2 |
| Kudo, M | 1 |
| Gerken, G; Katsounas, A; Kottilil, S; Lempicki, RA; Polis, M; Schlaak, JF; Trippler, M; Wang, B | 1 |
| Ceauşu, E; Gheorghe, L; Iliescu, L; Mateescu, B; Micu, L; Mocan, T; Pascu, O; Seicean, A; Voiculescu, M | 1 |
| Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM | 1 |
| Cipriano, LE; Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Owens, DK | 1 |
| Balistreri, W; Barton, BA; Duggan, C; Gonzalez-Peralta, RP; Haber, B; Jonas, MM; Lobritto, S; Mitchell, PD; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB; Shepherd, JA | 1 |
| Peck-Radosavljevic, M; Reiberger, T | 1 |
| Alberti, AB; Belli, LS; Burra, P; Burroughs, AK; Cillo, U; De Carlis, L; De Martin, E; Fagiuoli, S; Graziadei, I; Gridelli, B; Guido, M; Lerut, J; Pasulo, L; Pinzello, G; Starkel, P; Vogel, W; Volpes, R | 1 |
| Bai, XF; Hao, CQ; Jia, ZS; Kang, WZ; Li, B; Ma, L; Pan, L; Peng, XJ; Wei, X; Xie, YM; Zhang, Y | 1 |
| Fazio, V; Giannini, EG; Marenco, S; Picciotto, A; Pieri, G; Savarino, V | 1 |
| Guarascio, P; Pellicelli, AM; Romano, M; Vignally, P | 1 |
| Aghemo, A; Colombo, M; De Nicola, S; Dongiovanni, P; Fargion, S; Ferenci, P; Maggioni, P; Motta, BM; Rumi, MG; Stättermayer, AF; Valenti, L | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M | 1 |
| Boillot, O; Botta-Fridlund, D; Boudjema, K; Calmus, Y; Chazouillères, O; Dharancy, S; Durand, F; Duvoux, C; Gugenheim, J; Néau-Cransac, M; Pageaux, G; Rostaing, L; Samelson, L; Samuel, D; Vanlemmens, C; Wolf, P | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Grancini, V; Orsi, E; Prati, GM; Rumi, MG; Soffredini, R | 1 |
| Berak, H; Dusheiko, GM; Ferenci, P; Gane, EJ; Hadziyannis, SJ; Han, KH; Harley, HA; Horsmans, YJ; Husa, P; Jenny Heathcote, E; Lee, SS; Messinger, D; Roberts, SK; Tatsch, F | 1 |
| Bukh, J; Christensen, PB; Krarup, HB; Krogsgaard, K; Laursen, AL; Madsen, PH; Orholm, M; Pedersen, C; Ring-Larsen, H; Schlichting, P | 1 |
| Bellia, C; Cabibi, D; Cammà, C; Caruso, A; Ciaccio, M; Craxì, A; Di Marco, V; Mazzola, A; Petta, S | 1 |
| Bibert, S; Bochud, PY; Guedj, H; Guedj, J; Lagging, M; Negro, F; Neumann, AU; Westin, J | 1 |
| Cacoub, P; Geri, G; Imbert-Bismut, F; Poynard, T; Saadoun, D; Sène, D; Terrier, B | 1 |
| Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Naishadham, D; Shiffman, ML; Szabo, G; Wright, EC | 1 |
| Bashir, S; Hamid, S; Mirza, S; Siddiqui, AR; Umar, M | 1 |
| El Saadany, S; Enaba, M; Ghazy, M; Hasan, A; Ziada, DH | 1 |
| Bailly, F; Zoulim, F | 1 |
| Liu, GW; Ma, SP; Wang, CF; Zhao, WX | 1 |
| Buti, M; Deltenre, P; Deuffic-Burban, S; Hatzakis, A; Mathurin, P; Moreno, C; Mühlberger, N; Parkes, J; Rosenberg, W; Siebert, U; Stroffolini, T; Zeuzem, S | 1 |
| Liu, N; Liu, P; Sun, C; Wen, Y | 1 |
| Naveau, S; Perlemuter, G; Voican, CS | 1 |
| Chen, DS; Chen, JH; Chen, PJ; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, SS | 1 |
| Jabłonowska, E; Koślińska-Berkan, E; Omulecka, A; Piekarska, A; Szymańska, B; Wójcik, K | 1 |
| Chang, CK; Hsieh, YH; Hung, TH; Lai, NS; Tseng, CW; Tseng, KC; Wu, SF | 1 |
| Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Schmied, B; Sieghart, W; Trauner, M | 1 |
| de los Santos-Gil, I; García-Rey, S; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Bahra, M; Boas-Knoop, S; Eurich, D; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, UP; Puhl, G; Trautwein, C; Wasmuth, H; Yahyazadeh, A | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kobayashi, T; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Chen, CH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JH | 1 |
| Bociąga-Jasik, M; Cibor, D; Cieśla, A; Głowacki, MK; Mach, T; Owczarek, D; Sanak, M; Sobczyk-Krupiarz, I | 1 |
| Alfaleh, FZ; Alghamdi, AS; Alghamdi, H; Alqutub, A; Alswat, K; Altraif, I; Ismail, M; Sanai, FM; Shah, H | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Andersen, JW; Butt, AA; Chung, RT; Hua, L; Kemmer, N; Sherman, KE | 1 |
| Asensi, V; Cartón, JA; Collazos, J; de la Fuente, B | 1 |
| Bárcena, R; Casado, JL; Del Campo, S; Dronda, F; Mateos, ML; Montes, M; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Derbala, MF; Rizk, NM | 1 |
| Awad, AB; Awad, T; Doss, W; El-Akel, W; Mabrouk, M; Radwan, A; Zayed, N | 1 |
| Akahoshi, T; Fukuhara, T; Furusyo, N; Hayashi, J; Ikegami, T; Maehara, Y; Motomura, T; Shirabe, K; Soejima, Y; Tomikawa, M; Yoshizumi, T | 1 |
| Andreoli, A; Barbarini, G; Barbaro, G; Barlattani, A; Bonaventura, ME; D'Ambrosio, C; Furlan, C; Gentilucci, UV; Marignani, M; Mastropietro, C; Mazzoni, E; Mecenate, F; Miglioresi, L; Mitidieri, O; Monarca, R; Nosotti, L; Pellicelli, AM; Picardi, A; Puoti, C; Romano, M; Stroffolini, T; Vignally, P | 1 |
| Bochud, PY; Clément, S; Conzelmann, S; Dill, MT; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pascarella, S; Pawlotsky, JM; Rubbia-Brandt, L; Zeuzem, S | 1 |
| Button, P; Cheng, WS; Crawford, DH; Dore, GJ; George, J; Kitson, MT; McCaughan, GW; Roberts, SK; Sievert, W; Weltman, MD | 1 |
| Albrecht, JK; Bacon, B; Brass, CA; Bruno, S; Burroughs, MH; Esteban, R; Goodman, Z; Gottesdiener, K; Nyberg, LM; Pedicone, LD; Poordad, F; Tanno, H; Thompson, S; Vierling, JM | 1 |
| Asselah, T | 2 |
| Terrault, N | 1 |
| Tillmann, HL | 1 |
| Albert, J; Bojunga, J; Dultz, G; Forestier, N; Friedrich-Rust, M; Gaus, A; Gerber, L; Herrmann, E; Poynard, T; Sarrazin, C; Schneider, MD; Zeuzem, S | 1 |
| Chmura, A; Cieciura, T; Lisik, W; Pacholczyk, M; Tronina, O; Wasiak, D; Łągiewska, B | 1 |
| Chopra, A; Drinnan, T; Klein, PL; Lee, SS | 1 |
| Aghemo, A; Grassi, E | 1 |
| Bourlière, M; Bronowicki, JP; Fontaine, H; Hézode, C; Pol, S; Wendt, A | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Grimaudo, S; Pipitone, RM | 1 |
| Alejji, K; Alkaabi, S; Almohanadi, M; Butt, M; Derbala, M; Eldweik, N; John, A; Rizk, N; Sharma, M; Shebl, F; Yaqoob, R | 1 |
| Hige, S; Ikehara, Y; Ito, K; Kage, M; Kuno, A; Matsuda, A; Mizokami, M; Narimatsu, H; Sakamoto, M; Sekiya, S; Tanaka, Y | 1 |
| Szabó, A; Tusnádi, A | 1 |
| Karatapanis, S; Lisgos, P; Papastergiou, V; Prodromidou, K; Pselas, C; Stampori, M | 1 |
| Brochier, J; Flexman, J; French, MA; Jeffrey, GP; Keane, NM; Lee, S; Macquillan, GC; Price, P | 1 |
| Akremi, R; Benhamou, JP; Bourliere, M; Ibrahim, A; Katz, GG; Malkiewicz, I; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH; Spircu, T | 1 |
| Perlemuter, G | 1 |
| Gervais, A | 1 |
| Bronowicki, JP | 1 |
| Dhumeaux, D; Lerebours, E; Marcellin, P | 1 |
| Durand, F | 1 |
| Zeuzem, S | 2 |
| Angelico, M; Araco, A; Bergamini, A; Bolacchi, F; Cepparulo, M; Ombres, D; Rocchi, G; Tisone, G | 1 |
| Wright, TL | 1 |
| Malfertheiner, P | 1 |
| Cornberg, M; Manns, MP; Wedemeyer, H; Wiegand, J | 1 |
| Poynard, T | 2 |
| Gonvers, JJ; Pache, I | 1 |
| Myers, RP; Poynard, T; Thibault, V | 1 |
| Curran, MP; Keating, GM | 1 |
| Blazek, J; Eason, J; Khan, S; Lipscomb, J; Loss, G; Mason, A; Nair, S | 1 |
| Adinolfi, LE; Ruggiero, G; Tonziello, A; Utili, R | 1 |
| Färkkilä, M | 1 |
| Durand, D; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J | 1 |
| Forns, X; Martínez-Bauer, E | 1 |
| Capra, F; De Maria, E; Franchini, M; Marchiori, L; Thalheimer, U; Vantini, I | 1 |
| Flamm, SL | 1 |
| Bekkering, FC; Brouwer, JT; Hansen, BE; Schalm, SW; Vrolijk, JM | 1 |
| Hrachovec, J; Patel, P | 1 |
| Bendtsen, F; Holten-Andersen, M; Johansen, JS; Krarup, HB; Møller, A; Nøjgaard, C | 1 |
| Barbare, JC | 1 |
| Goldie, SJ; Hammitt, JK; Salomon, JA; Weinstein, MC | 1 |
| Saab, S; Wang, V | 1 |
| Arif, A; Bank, L; Gregory, DH; Levine, RA; Mahl, TC; Sanderson, SO; Shah, A; Velu, RP | 1 |
| Zhang, F | 1 |
| Albrecht, J; Manns, M; McHutchison, J; Myers, RP; Poynard, T | 1 |
| Desmet, VJ; Roskams, T | 1 |
| de la Mata, M; Feliu, A; Forns, X; García-Retortillo, M; García-Valdecasas, JC; Navasa, M; Rimola, A; Rodés, J; Serrano, T; Suarez, F | 1 |
| Bressler, BL; Guindi, M; Heathcote, J; Tomlinson, G | 1 |
| Maier, KP | 1 |
| Bajaj, JS; Jeffers, LJ; Molina, E; Regev, A; Schiff, ER | 1 |
| Sorrell, M; Villamil, F; Wiesner, RH | 1 |
| Davis, GL | 1 |
| Busuttil, RW; Saab, S | 1 |
| Adler, M; Bastens, B; Bourgeois, N; Brenard, R; Brouwer, J; Bruckers, L; Colle, I; de Galocsy, C; de Vries, RA; Delwaide, J; Henrion, J; Horsmans, Y; Leroux-Roels, G; Michielsen, P; Nevens, F; Robaeys, G; Van Vlierberghe, H | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| Bedossa, P; Bréchot, C; Carnot, F; Fontaine, H; Lagneau, JL; Nalpas, B; Pol, S; Serfaty, L; Serpaggi, J | 1 |
| Halota, W; Pawłowska, M | 1 |
| Benedict Cosimi, A; Bhan, AK; Chung, RT; Pascual, M; Ross, AS; Thiim, M | 1 |
| Everson, GT; Fontana, RJ; Shiffman, ML; Tuteja, S; Vargas, HE | 1 |
| Boillot, O; Chevallier, P; Dumortier, J; Scoazec, JY | 1 |
| Bahr, MJ; Manns, MP | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everhart, JE; Everson, GT; Ghany, MG; Goodman, ZD; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC | 1 |
| Benhamou, Y; Bochet, M; Mehri, D; Myers, RP; Poynard, T; Thibault, V | 1 |
| Everson, GT | 1 |
| Ammassari, A; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Fantoni, M; Marasca, G; Tamburrini, E; Tumbarello, M | 1 |
| Hegenbarth, K; Ille, R; Krause, R; Lahousen, T; Lipp, RW; Little, RR; Schnedl, WJ | 1 |
| Cupelli, L; DePamphilis, J; Dieterich, D; Duff, F; Larrey, D; Mauss, S; Passe, S; Solsky, J; Torriani, FJ; Valenti, W | 1 |
| Fontana, RJ | 1 |
| Cheng, SX; Dhar, AD; Klaus, SN; Werchniak, AE | 1 |
| Dillon, JF | 1 |
| Kondo, Y; Omata, M; Tateishi, R; Yoshida, H | 1 |
| Yamada, G | 1 |
| Makuuchi, M; Sugawara, Y | 3 |
| Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Mariuzzi, L; Minisini, R; Pirisi, M; Toniutto, P | 1 |
| Alegría, S; Brahm, J; Buckel, E; Ceresa, S; Ferrario, M; Smok, G | 1 |
| Rókusz, L | 1 |
| Accogli, E; Azzaroli, F; Colecchia, A; Derenzini, M; Festi, D; Giovanelli, S; Lodato, F; Mazzella, G; Miracolo, A; Montagnani, M; Mwangemi, C; Nigro, G; Roda, E; Tamé, M; Trere, D | 1 |
| Blum, HE; Moradpour, D | 1 |
| Hayes, P; Teo, M | 1 |
| McHutchison, JG; Patel, K | 1 |
| Shiffman, ML | 2 |
| Abergel, A; Bommelaer, G; Bonny, C; Bronowicki, JP; Canva, V; Chevallier, M; Darcha, C; de Ledinghen, V; Dechelotte, P; Henquell, C; Lafeuille, H; Martineau, N; Pol, S; Tran, A; Ughetto, S | 1 |
| Gudinaviciene, I; Jonaitis, L; Kupcinskas, L; Petrenkiene, V | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Leitz, G; Mody, SH; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, TL; Younossi, Z | 1 |
| Antela, A; Bárcena, R; Blázquez, J; del Campo, S; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, L; Moreno, S; Perez-Elías, MJ; Quereda, C; Sánchez, J | 1 |
| Alaric, L; Bureau, C; Péron, JM; Pey, F; Valmary, S; Vinel, JP; Zabraniechki, L | 1 |
| Afdhal, N; Kelleher, TB | 1 |
| Ferenci, P; Gangl, A; Gasche, C; Grundtner, P; Hofer, H; Neufeld, JB; Oesterreicher, C; Wrba, F | 1 |
| de Knegt, RJ; Eijkemans, MJ; Habbema, JD; Hansen, BE; Schalm, SW; Stijnen, T; Veldt, BJ | 1 |
| González-Lahoz, J; Soriano, V | 1 |
| Karpov, SIu; Krel', PE | 1 |
| Andrade, RJ; Castillo, J; Corpas, R; Cruz, M; Del Mar Viloria, M; Diago, M; Fernández-Rodríguez, CM; Gila, A; Grande, L; Gutiérrez, ML; López-Serrano, P; Muñoz-De-Rueda, P; Pérez, C; Romero-Gómez, M; Ruiz-Extremera, A; Salmerón, J; Suárez, E; Vázquez, L | 1 |
| Boulestin, A; Chatelut, E; Durand, D; Esposito, L; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J; Stébenet, M | 1 |
| Anatol, P; Danuta, P; Robert, F | 1 |
| Flisiak, R | 1 |
| Boullosa Graña, E; Cuervas-Mons Martínez, V; Fernández Ruiz, M; Jiménez Garrido, M; Lucena de la Poza, JL; Martínez Arrieta, F; Molina Miliani, C; Moreno Planas, JM; Rubio González, E; Sánchez Turrión, V | 1 |
| Allende, H; Bilbao, I; Castells, L; Esteban, R; Guardia, J; Luis Lázaro, J; Margarit, C; Vargas, V | 1 |
| Barrios Peinado, C; Boullosa Graña, E; Cuervas-Mons Martinez, V; Garrido Botella, A; Jiménez Garrido, M; Lucena Poza, JL; Moreno Planas, JM; Rubio Gonzalez, E; Sanchez Turrion, V | 1 |
| D'Souza, R; Foster, GR; Sabin, CA | 1 |
| Boyer, N; Cazals-Hatem, D; Consigny, Y; Degott, C; Marcellin, P; Marrache, F; Martinot, M; Ripault, MP; Valla, D | 1 |
| Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C; Zoulim, F | 1 |
| Ferenci, P | 1 |
| Jeong, SH; Suh, DJ | 1 |
| Covino, M; Gasbarrini, G; Larocca, LM; Pizzolante, F; Pompili, M; Rapaccini, GL | 1 |
| Adamski, M; Dziecioł, J; Panasiuk, A; Prokopowicz, D | 1 |
| Jankowska, I; Pawłowska, J; Rokitka, M; Socha, J; Sokal, E; Teisseyre, M | 1 |
| Cengiz, C; Dieterich, DT; Park, JS; Saraf, N | 1 |
| Bárcena, R; Blázquez, J; Foruny, JR; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, S; Muriel, A; Pérez-Elías, MJ; Quereda, C; Rodriguez-Sagrado, MA; Sánchez, J | 1 |
| Chen, K; Chiou, CF; Robbins, S; Spiegel, BM; Younossi, ZM | 1 |
| Ołdakowska-Jedynak, U; Paczek, L | 1 |
| Garcia-Samaniego, J; Maida, I; Martin-Carbonero, L; Nuñez, M; Soriano, V | 1 |
| Ostojić, R | 1 |
| Caprio, N; Iannicelli, P; Martini, S; Mogavero, AR; Pasquale, G | 1 |
| Alter, H | 1 |
| Dieterich, DT; Park, JS; Saraf, N | 1 |
| Lawson, A; Ryder, SD | 1 |
| Stadlbauer, V; Stauber, RE | 1 |
| Boroń-Kaczmarska, A; Jurczyk, K; Karpińska, E; Morańska, I; Urbanowicz, W; Wawrzynowicz-Syczewska, M | 1 |
| Ahmad, J; Anand, BS; Awad, JA; Aytaman, A; Bini, EJ; Bräu, N; Chang, KM; Cheung, RC; Currie, S; Hagedorn, CH; Ho, SB; Hu, KQ; Jeffers, LJ; Johnson, DP; King, PD; Mendenhall, CL; Morgan, TR; Moseley, RH; Pedrosa, MC; Rossi, SJ; Schmidt, WN; Shen, H; Simon, FR; Waters, B; Wright, TL | 1 |
| Herrmann, E; Mihm, U; Sarrazin, C; Zeuzem, S | 1 |
| Carreño, V; Castillo, I; López-Alcorocho, JM; Pardo, M; Perez-Mota, A; Rodríguez-Iñigo, E | 1 |
| Tulassay, Z; Werling, K | 1 |
| Arakawa, Y; Moriyama, M | 1 |
| Abud-Bastida, F; Constantino-Casas, P; García-Contreras, F; Garduño-Espinosa, J; Nevárez-Sida, A | 1 |
| Lyden, E; Mukherjee, S | 1 |
| Ruiz-Sancho, A; Soriano, V | 1 |
| Bräu, N; Dieterich, DT; Green, J; Hornberger, J; Patel, K; Sulkowski, MS; Torres, MR; Torriani, FJ | 1 |
| Arn, M; Borovicka, J; Criblez, D; Egger, H; Gonvers, JJ; Helbling, B; Meyenberger, C; Meyer-Wyss, B; Müllhaupt, B; Oneta, C; Rammert, C; Renner, EL; Rich, P; Rossi, L | 1 |
| Chung, RT; O'Leary, JG | 1 |
| Bejarano, PA; Casanova-Romero, PY; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER; Tzakis, AG | 1 |
| Chayama, K; Imamura, M | 1 |
| Farci, P; Green, J; Hornberger, J; Patel, KK; Prati, D; Zeuzem, S | 1 |
| Changchien, CS; Chen, CH; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Daruich, J; Fainboim, H; Frider, B | 1 |
| Berenguer, M; Terrault, NA | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everhart, JE; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC | 1 |
| Amaral, AC; Conceição, RD; de Oliveira, AC; Leite, K; Parise, ER | 1 |
| Bärthel, E; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 2 |
| Andriulli, A; Bjøro, K; Dalgard, O; Mangia, A | 1 |
| Bottari, S; Hilleret, MN; Leroy, V; Morel, F; Sturm, N; Trocme, C; Zarski, JP | 1 |
| Al Kaabi, SR; Al-Marri, A; Amer, AM; Bener, A; Butt, MT; Derbala, MF; El Dweik, NZ; Morad, N; Pasic, F; Yakoob, R | 1 |
| Alvarez, E; Bañares, R; Catalina, MV; Clemente, G; Lo Iacono, O; Matilla, AM; Nuñez, O; Rincon, D; Ripoll, C; Salcedo, M | 1 |
| Andrade, Z; Codes, L; Cruz, M; de Freitas, LA; Paraná, R; Schinoni, MI; Trepo, C | 1 |
| Borovicka, J; Cerny, A; Dinges, S; Esteban, A; Gonvers, JJ; Helbling, B; Jochum, W; Knöpfli, M; Meyer-Wyss, B; Müllhaupt, B; Renner, EL; Stamenic, I; Wilhelmi, M | 1 |
| Barreiro, P; Garcia-Samaniego, J; Labarga, P; Ruiz-Sancho, A; Soriano, V | 1 |
| Abergel, A; Alric, L; Barange, K; Bernard, PH; Bommelaer, G; Bonny, C; Bronowicki, JP; Castera, L; Chevallier, M; Darcha, C; Dhumeaux, D; Dubost, S; Henquell, C; Hezode, C; Lafeuille, H; Leroy, V; Martineau, N; Randl, K; Tran, A; Ughetto, S | 1 |
| Carulli, N | 1 |
| Balzola, F; Bellati, G; Benetti, G; Borzio, M; Colombo, A; Croce, G; Fargion, S; Iamoletti, C; Ramella, G; Rizzetto, M | 1 |
| Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Leandro, G; Perri, F; Siciliano, M | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Kahn, JA; Lee, WM; Lok, AS; Morishima, C; Naishadham, D; Seeff, LB; Shiffman, ML | 1 |
| Bergholz, U; Ferenci, P; Gurguta, C; Hofer, H; Steindl-Munda, P | 1 |
| Carrilho, FJ; da Silva, LC; de Carvalho Mello, IM; de Mello Malta, F; Medeiros-Filho, JE; Neumann, AU; Pinho, JR | 1 |
| Hu, Z; Kleiner, DE; Koratich, C; Kottilil, S; Lempicki, R; Masur, H; McLaughlin, M; Polis, MA; Rehm, CA; Reitano, KN; Wood, B; Wu, L; Yang, J | 1 |
| Berg, T; Bergk, A; Halangk, J; Hinrichsen, H; Müller, T; Neuhaus, P; Neumann, K; Puhl, G; Schott, E; Tinjala, S; Weich, V; Wiedenmann, B; Witt, H | 1 |
| Baulieux, J; Bizollon, T; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C | 1 |
| Asselah, T; Belghiti, J; Boudjema, H; Durand, F; Francoz, C; Marcellin, P; Sobesky, R; Valla, D | 1 |
| Back-Madruga, C; Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Gretch, DR; Kulig, CC; Malet, PF; Morgan, TR; Snow, KK; Sterling, RK | 1 |
| Bini, EJ; Bräu, N; Cheung, RC; Currie, SL; Ho, SB; Hu, KQ; Jeffers, L; McCracken, JD; Morgan, T; Schmidt, WN; Shen, H; Wright, TL | 1 |
| Alves de Mattos, A; Ferrari de Oliveira Rigo, J; Galperim, B; Lerias de Almeida, PR; Ribeiro de Souza, A; Riegel Santos, B; Valle Tovo, C | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC | 1 |
| Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Padmanabhan, L; Shiffman, ML | 1 |
| Bahra, M; Berg, T; Jacob, D; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, UP | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG; Soffredini, R | 1 |
| Franchini, M | 1 |
| Mátyus, J; Tornai, I | 1 |
| Bortolotti, F; Guido, M | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot, M; Ripault, MP | 1 |
| Barreiros, AP; Biesterfeld, S; Böcher, WO; Galle, PR; Greif-Higer, G; Kanzler, S; Lohse, AW; Mönch, C; Otto, G; Schuchmann, M; Sprinzl, MF; Wörns, MA; Zimmermann, A; Zimmermann, T | 1 |
| Chao, PL; Chen, TM; Ho, KS; Huang, PT; Lin, LF; Liu, CC; Siauw, CP; Tsai, MH; Tung, JN | 1 |
| Almasio, PL; Amato, M; Craxí, A; De Lisi, S; Di Marco, V; Ferraro, D; Giordano, C; Lo Iacono, O; Mineo, C; Petta, S; Rodolico, V; Venezia, G | 1 |
| Alsiö, A; Ferrari, C; Hellstrand, K; Lagging, M; Neumann, AU; Pawlotsky, JM; Schalm, SW; Verhey-Hart, E; Westin, J; Ydreborg, M; Zeuzem, S | 1 |
| Bosch, J; Bruguera, M; Carrión, JA; Crespo, G; Forns, X; García-Pagan, JC; García-Retortillo, M; Navasa, M | 1 |
| Benhamou, Y; Sulkowski, MS | 1 |
| Benhamou, Y; Bräu, N; Cargnel, A; Hatzakis, A; Mauss, S; Peters, M; Pol, S; Puoti, M; Rockstroh, J; Soriano, V; Sulkowski, M | 1 |
| Angus, P; Bowden, S; Gordon, A; McLean, C; Pedersen, J; Roberts, S; Thomson, K | 1 |
| Chowaniec, E; Radziszewski, A; Sułowicz, W | 1 |
| Baazia, Y; Bailly, F; Bourcier, V; Bourlière, M; Castera, L; De Ledinghen, V; Deny, P; Fontaine, H; Grando, V; Marcellin, P; Poupon, R; Roudot-Thoraval, F; Roulot, D; Zarski, JP | 1 |
| Dahari, H; Perelson, AS | 1 |
| Barreiro, P; Casado, R; Castellares, C; Garcia-Gasco, P; Labarga, P; Maida, I; Martin-Carbonero, L; Pinilla, J; Soriano, V; Vispo, ME | 1 |
| Berak, H; Horban, A; Kołakowska-Rzadzka, A; Krzysztof, B; Stańczak, JJ; Walewska-Zielecka, B; Wasilewski, M | 1 |
| Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Peralta, S | 1 |
| Janczewska-Kazek, E; Kajdaniuk, D; Magiera, M; Marek, B; Pisula, A; Witor, A | 1 |
| Alagna, L; De Bona, A; Galli, L; Gallotta, G; Guzzo, A; Lazzarin, A; Uberti-Foppa, C | 1 |
| Basile, V; Capone, D; Conca, P; Cuocolo, A; Di Minno, MN; Gentile, A; Tarantino, G; Tarantino, M | 1 |
| Andreone, P; Bernardi, M; Biselli, M; Cursaro, C; Gramenzi, A; Scuteri, A; Serra, C; Vitale, G; Vukotic, R | 1 |
| Lengyel, G; Tulassay, Z | 1 |
| Doros, A; Fazakas, J; Fehér, J; Fehérvári, I; Gálffy, Z; Gerlei, Z; Görög, D; Járay, J; Lengyel, G; Lotz, G; Máthé, Z; Nagy, P; Nemes, B; Németh, A; Pár, A; Sárváry, E; Schaff, Z; Schuller, J; Telegdy, L | 1 |
| Coppola, N; Piccinino, F | 1 |
| Beaugrand, M; Braks, RE; Fontaine, H; Ganne-Carrie, N; Grando-Lemaire, V; Paries, J; Pol, S; Trinchet, JC | 1 |
| Basgoz, N; Bica, I; Birch, C; Davis, B; Gandhi, RT; Graeme-Cook, F; McGovern, BH; Quirk, JR; Stone, D; Zachary, K; Zaman, MT | 1 |
| Brandt, LR; Cua, IH; George, J; Hui, J; Kench, JG; Negro, F; Poustchi, H | 1 |
| Buzatu, E; Cooper, CL; Dudas, J; Esguerra, R; Gorrell, MD; Haber, PS; Hilzenrat, N; Ionescu, C; Leo, MA; Lieber, CS; McCaughan, GW; Neuman, MG; Ramadori, G; Saile, B; Seth, D; Sha, K; Voiculescu, M; Winkler, RE; Wyse, J; Zakhari, S | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG | 1 |
| Hansen, BE; Heathcote, EJ; Hofmann, WP; Janssen, HL; Manns, MP; Reichen, J; Schalm, SW; Veldt, BJ; Wedemeyer, H; Zeuzem, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Cummings, OW; Kwo, PY; Saxena, R; Tector, AJ | 1 |
| Battegay, E; Mettler, J; Zimmerli, L | 1 |
| Abdo, N; Antaki, F; Antaki, N; Ftayeh, M; Hadad, M; Hermes, A; Kebbewar, K | 1 |
| Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML | 1 |
| Kim, HJ | 1 |
| Ahn, CS; Choi, KM; Chung, YH; Hwang, S; Kim, KH; Lee, SG; Lee, YS; Moon, DB; Park, JI; Suh, DJ | 1 |
| Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M | 1 |
| Bemba, G; Kautz, A; Niederau, C | 1 |
| Casado, J; Diago, M; Gila, A; Lafuente, V; León, J; Palacios, A; Quiles, R; Rodriguez, L; Romero-Gómez, M; Rueda, PM; Ruiz-Extremera, A; Salmerón, J | 1 |
| Cacoub, P; Saadoun, D; Sène, D | 1 |
| Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; De Boever, CM; Halfon, P; Lapidus, N; Perronne, C; Pol, S | 1 |
| Baldo, V; Baldovin, T; Carderi, I; Floreani, A; Minola, E; Rizzotto, ER | 1 |
| Amoruso, D; Caporaso, N; Morisco, F; Stroffolini, T | 1 |
| Abate, ML; Baldi, I; Balzola, F; Ciancio, A; Ciccone, G; Pellicano, R; Puglisi, G; Rizzetto, M; Saracco, G; Smedile, A | 1 |
| Antonaci, A; Antonaci, S; Giannelli, G; Napoli, N | 1 |
| Abenavoli, L; Abenavoli, SM; De Maria, V; De Siena, M; Di Salvo, S; Giancotti, F; Gravina, T | 1 |
| Aghemo, A; Colombo, M; Rumi, MG | 1 |
| Akarca, U; Ersoz, G; Gunsar, F; Karasu, Z; Tekin, F | 1 |
| Chen, HY; Li, J; Rao, HY; Sun, Y; Wang, H; Wei, L; Zhang, LF; Zhu, LM | 1 |
| Abdel-Hamid, M; Attala, M; El Hoseiny, M; El Makhzangy, H; Esmat, G; Fontanet, A; Gad, RR; Hasan, A; Males, S; Mohamed, MK; Shouman, S; Zalata, K | 1 |
| Sherlock, S | 1 |
| Blot, C; Mathurin, P; Moussalli, J; Opolon, P; Perrin, M; Plassart, F; Poynard, T; Thevenot, T | 1 |
| Sharara, AI | 1 |
| Brouwer, JT; Fattovich, G; Schalm, SW | 1 |
| Brown, JL | 1 |
| Bouloux, P; Hoffbrand, AV; Jensen, C; Telfer, P; Wonke, B | 1 |
| Berg, T; Götz, G; Haefker, A; Hopf, U; Neuhaus, P; Neuhaus, R; Schön, MR | 1 |
| Azoulay, D; Charpentier, B; Debuire, B; Ducret, F; Féray, C; Gigou, M; Lemoine, A; Paradis, V; Pham, HP; Samuel, D | 1 |
| Brenard, R; Closon, ML; Fevery, J; Hautekeete, M | 1 |
| Batey, RG; Sievert, W | 1 |
| Al Ashgar, H; Cattral, MS; Greig, PD; Hemming, AW; Krajden, M; Levy, GA; Lilly, L; Wanless, IR | 1 |
| Chapman, RW; Christie, JM | 1 |
| Bellobuono, A; Brouwer, JT; Chemello, L; Chen, DS; Hansen, BE; Hollander, A; Lai, MY; Michielsen, PP; Milella, M; Pastore, G; Schalm, SW; Weiland, O | 1 |
| Silvain, C | 1 |
| Görög, D; Horányi, M; Schaff, Z; Telegdy, L | 1 |
| Bjøro, K; Frøland, SS; Haaland, T; Skaug, K | 1 |
| Lawrence, SP | 1 |
| Paul, A | 1 |
| Burroughs, AK; Papatheodoridis, GV; Pastacaldi, S; Teixeira, R | 1 |
| Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C | 1 |
| Koshy, A; Madda, JP; Marcellin, P; Martinot, M | 2 |
| Albrecht, J; Bedossa, P; Davis, GL; Esteban-Mur, R; Goodman, Z; McHutchison, J; Poynard, T | 1 |
| Cote, J; Dagenais, M; Hassoun, Z; Lapointe, R; Letourneau, R; Marleau, D; N'Guyen, B; Roy, A; Villeneuve, JP; Willems, B | 1 |
| Agarwal, K; Bassendine, DR; Bassendine, MF; Burt, AD; Craig, W; Gilvarry, E; Hewett, M; Jowett, SL; Smith, BC | 1 |
| Pérez, R; Rodríguez, M | 1 |
| Gómez, M; Otero, A; Souto, J; Suárez, FJ; Vázquez-Iglesias, JL | 1 |
| Burroughs, AK; Papatheodoridis, GV; Teixeira, R | 1 |
| Fontaine, H; Pol, S; Vallet-Pichard, A | 1 |
| Seeff, LB; Strader, DB | 1 |
| Chapman, R; Collier, J | 1 |
| Cornberg, M; Manns, MP; Wedemeyer, H | 1 |
| Tanikawa, K | 1 |
| Airoldi, A; Alberti, AB; Belli, LS; Cernuschi, A; D'Amico, M; de Carlis, L; Forti, D; Minola, E; Pinzello, G; Rondinara, G; Vangeli, M | 1 |
| Niederau, C | 1 |
| Rodés, J; Sánchez Tapias, JM | 1 |
| Koczorek, M | 1 |
| Akremi, R; Asselah, T; Benali, S; Benhamou, JP; Bourliere, M; Boyer, N; Ibrahim, A; Katz, GG; Le Breton, V; Le Guludec, G; Lecomte, L; Malkiewicz, I; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH | 1 |
| Mollison, L; Olynyk, J; Totten, L; Yusoff, IF | 1 |
| Bernard, PH; Bourlière, M; Canva, V; Capron, D; Chêne, G; Couzigou, P; de Lédinghen, V; Desmorat, H; Fleury, H; Foucher, J; Lévy, S; Mannant, PR; Mion, F; Trimoulet, P; Winnock, M | 1 |
| Albrecht, J; Goodman, Z; Lindsay, K; Ling, MH; Manns, M; McHutchison, J; Poynard, T; Trepo, C | 1 |
| Arthur, MJ | 1 |
| Forns, X | 1 |
| Abergel, A; Bernard, PH; Bourlière, M; Chêne, G; Couzigou, P; de Lédinghen, V; Fleury, H; Lévy, S; Portal, I; Rémy, AJ; Szostak, N; Tran, A; Trimoulet, P; Winnock, M | 1 |
| Giostra, E; Mentha, G; Negro, F; Rizzoli, R; Trombetti, A | 1 |
| Barrera, JM; Campistol, JM; Esforzado, N; Morales, JM | 1 |
193 review(s) available for ribavirin and Cirrhosis, Liver
| Article | Year |
|---|---|
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Ribavirin | 2023 |
Interferon-Free Hepatitis C Virus Therapy.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Practice Guidelines as Topic; Ribavirin; Sustained Virologic Response | 2020 |
A PRISMA-compliant systematic review and meta-analysis of integrated Chinese and Western medicine in treating hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Combined Modality Therapy; Drug Therapy, Combination; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Medicine, Chinese Traditional; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serum Albumin | 2020 |
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Renal Insufficiency, Chronic; Ribavirin | 2017 |
Direct-acting antivirals: the endgame for hepatitis C?
Topics: Antiviral Agents; Disease Eradication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2017 |
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
Topics: Anilides; Antiviral Agents; Carbamates; Comorbidity; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2017 |
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2017 |
Impact of etiological treatment on prognosis.
Topics: Alcohol Abstinence; Antiviral Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Portal Pressure; Prognosis; Ribavirin | 2018 |
Role of ribavirin in interferon-free therapy for the treatment of hepatitisC virus.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Observational Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Time Factors; Young Adult | 2018 |
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
Topics: Antiviral Agents; Azathioprine; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2013 |
[Progress in hepatitis C treatment].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2013 |
[Organizational characteristics of treatment for chronic hepatitis in Hungary: Hepatitis Registry and Priority Index].
Topics: Antiviral Agents; Chronic Disease; Delivery of Health Care; Drug Therapy, Combination; Health Priorities; Hepatitis, Viral, Human; Humans; Hungary; Interferons; Liver Cirrhosis; Registries; Ribavirin; Risk Assessment; Risk Factors | 2013 |
[Telaprevir in treatment-naïve patients with HCV monoinfection].
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Young Adult | 2013 |
[Telaprevir in HCV-monoinfected patients with failure to prior treatment].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome | 2013 |
[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Drug Eruptions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Medical Futility; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Stevens-Johnson Syndrome; Viral Load | 2013 |
[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Topics: Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2013 |
Treatment of chronic hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Drug Interactions; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Proline; Ribavirin; Secondary Prevention | 2013 |
Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin | 2013 |
Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.
Topics: Antiviral Agents; Coinfection; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2014 |
[Therapy of chronic hepatitis C].
Topics: Adult; Algorithms; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Polyethylene Glycols; Prognosis; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2014 |
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2014 |
Hepatitis C.
Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2014 |
Virus-related liver cirrhosis: molecular basis and therapeutic options.
Topics: Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Genotype; Hepacivirus; Hepatic Stellate Cells; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Liver Cirrhosis; Mutation; Regeneration; Ribavirin; Stem Cells; Virus Replication | 2014 |
Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferons; Liver Cirrhosis; Polymorphism, Genetic; Research Design; Ribavirin; Viral Load | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine | 2015 |
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2015 |
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome | 2015 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors | 2014 |
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2015 |
Perspectives on dual hepatitis B and C infection in Taiwan.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome | 2016 |
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Transplantation; Recurrence; Renal Insufficiency; Ribavirin; Sofosbuvir | 2016 |
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2016 |
Why do I treat my patients with mild hepatitis C?
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2016 |
Why I do not treat patients for mild disease.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 2016 |
Is the benefit of treating patients with cirrhosis proven?
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2016 |
News and challenges in the treatment of hepatitis C in liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin | 2016 |
Hepatitis C virus: how to provide the best treatment with what I have.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult | 2016 |
Follow-up of patients with chronic hepatitis C and a sustained viral response.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Practice Guidelines as Topic; Republic of Korea; Ribavirin | 2016 |
Daclatasvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Hepatitis C virus: Promising discoveries and new treatments.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; RNA, Viral; Sustained Virologic Response; Viral Load | 2016 |
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
The impact of hepatitis C virus outside the liver: Evidence from Asia.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Costs and Cost Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Cirrhosis; Liver Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sustained Virologic Response; Treatment Failure | 2017 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Hepatitis C: efficacy and safety in real life.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Randomized Controlled Trials as Topic; Renal Insufficiency; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
[Therapy of chronic Hepatitis C in 2008].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2008 |
Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome; Viral Load | 2008 |
Clinical management of HIV/hepatitis C virus coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Health Services Needs and Demand; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Medication Adherence; Nurse Practitioners; Nurse's Role; Ribavirin; Risk Factors; Severity of Illness Index; Social Support | 2008 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
Treatment of chronic hepatitis C in Asia: when East meets West.
Topics: Antiviral Agents; Asia; Asian People; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People | 2009 |
The hepatitis C virus enigma.
Topics: Antigens, CD; Antiviral Agents; Biological Evolution; Disease Progression; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Receptors, Virus; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Tetraspanin 28; Viral Hepatitis Vaccines; Viremia; Virus Replication | 2009 |
Management of patients co-infected with HBV and HCV.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Superinfection; Treatment Outcome | 2009 |
[Novel treatments for hepatitis C viral infection and the hepatic fibrosis].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
New trends in hepatitis C management.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Carriers; Global Health; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2010 |
Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof.
Topics: Carcinoma, Hepatocellular; Chronic Disease; Clinical Trials as Topic; Hepacivirus; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Neoplasms; Randomized Controlled Trials as Topic; Ribavirin; Thymalfasin; Thymosin; Treatment Outcome | 2010 |
Telaprevir: a new hope in the treatment of chronic hepatitis C?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Synergism; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2010 |
Management of untreated and nonresponder patients with chronic hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2010 |
Current therapies for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Liver Cirrhosis; Male; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Treatment Outcome | 2011 |
Peginterferon and ribavirin treatment for hepatitis C virus infection.
Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.
Topics: Genetic Variation; Genome-Wide Association Study; Hepatitis C; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2011 |
Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cryoglobulinemia; Disease Progression; Drug Resistance, Viral; Female; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2011 |
Clinical practice. Chronic hepatitis C infection.
Topics: Antiviral Agents; Hepacivirus; Hepatitis B Antibodies; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
New treatments for chronic hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Serine Proteinase Inhibitors; Therapies, Investigational | 2011 |
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2011 |
Management of chronic hepatitis C infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Standard of Care | 2012 |
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indiana; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2012 |
Response-guided and -unguided treatment of chronic hepatitis C.
Topics: Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2012 |
Future treatment of patients with HCV cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2012 |
Hepatitis C virus treatment pre- and post-liver transplantation.
Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
What's new in HCV genotype 2 treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2012 |
The future for the treatment of genotype 4 chronic hepatitis C.
Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D | 2012 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Liver transplantation in the setting of chronic HCV.
Topics: Age Factors; Antiviral Agents; Cytomegalovirus Infections; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Protease Inhibitors; Ribavirin; Risk Factors; Secondary Prevention; Tissue Donors | 2012 |
How to optimize HCV therapy in genotype 1 patients: management of side-effects.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
How to optimize HCV therapy in genotype 2 patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2013 |
How to optimize HCV therapy in genotype 4 patients.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2013 |
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Phenotype; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
[Treatment of hepatitis C. Consensus conference].
Topics: Alcohol Drinking; Antiviral Agents; Drug Administration Schedule; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Patient Selection; Ribavirin; Severity of Illness Index | 2002 |
[Hepatitis C and alcohol].
Topics: Alanine Transaminase; Alcoholism; Antiviral Agents; Apoptosis; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Odds Ratio; Prevalence; Ribavirin; Risk Factors; Time Factors; Viral Load | 2002 |
[Chronic hepatitis C in HIV-HCV coinfected patients].
Topics: Adult; Age Factors; Amantadine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Meta-Analysis as Topic; Pilot Projects; Prevalence; Ribavirin; Risk Factors | 2002 |
[Treatment of hepatitis C virus-related cirrhosis].
Topics: Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Time Factors | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
[Treatment of patients with chronic hepatitis C who never had been treated].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biopsy; Body Weight; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Transaminases; Viral Load | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Mice; Mice, Transgenic; Multicenter Studies as Topic; Obesity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Smoking; Time Factors | 2002 |
[Hepatitis C and liver transplantation].
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Pilot Projects; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Tissue Donors; Transaminases | 2002 |
Treatment of patients with hepatitis C and cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver; Liver Cirrhosis; Liver Transplantation; Ribavirin | 2002 |
Polyethylene glycol-interferon: current status in hepatitis C virus therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
[Do the interferons have an antifibrotic action? The hepatologist's point of view].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterozygote; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
Topics: Adsorption; Antiviral Agents; Black People; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Drug therapy of hepatitis B and C].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2003 |
Chronic hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2003 |
Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Pegylated interferons in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Male; Mutation; Organophosphonates; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors | 2003 |
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Patient Selection; Practice Guidelines as Topic; Recurrence; Reoperation; Ribavirin; Risk Factors | 2003 |
New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation.
Topics: Animals; Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral; Secondary Prevention; Virus Replication | 2003 |
Practical management of liver transplant recipients for hepatitis C.
Topics: Antiviral Agents; Combined Modality Therapy; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; Treatment Outcome | 2003 |
Viral hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index | 2003 |
[Peginterferon alpha and ribavirin therapy for difficult-to-treat chronic hepatitis C patients].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2002 |
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Changing faces-natural course and treatment of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2004 |
Hepatitis C: What is the best treatment?
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2004 |
[Effectiveness of long-acting interferon (peginterferon)].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2004 |
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid | 2004 |
[Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
Topics: Antiviral Agents; Brain Death; Combined Modality Therapy; Drug Therapy, Combination; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Transplantation; Living Donors; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors | 2004 |
[Treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hungary; IMP Dehydrogenase; Interferons; Liver Cirrhosis; Liver Transplantation; Nucleosides; Ribavirin; Risk Factors | 2004 |
[Hepatitis C].
Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors | 2004 |
Management of hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Humans; Immunotherapy; Interferon-beta; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin | 2004 |
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.
Topics: Administration, Oral; Algorithms; Antiviral Agents; Clinical Trials as Topic; Drug Carriers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Compliance; Patient Selection; Polyethylene Glycols; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2004 |
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Topics: Adjuvants, Immunologic; Alcoholism; Amantadine; Antiviral Agents; Black or African American; Clinical Trials as Topic; Counseling; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferons; Liver Cirrhosis; Meta-Analysis as Topic; Oligonucleotides, Antisense; Patient Compliance; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; White People | 2004 |
Maintenance therapy for chronic hepatitis C.
Topics: Antiviral Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Long-Term Care; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Viral Load | 2005 |
Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Clinical Enzyme Tests; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin; Sex Factors | 2005 |
[Clinical characterization and peculiarities of the clinical course of low-activity hepatitis C].
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin | 2005 |
[Chance of hepatic fibrosis treatment in chronic hepatitis C].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Caspase Inhibitors; Cell Death; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2004 |
Current status of hepatitis C virus infection in Korea.
Topics: Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Korea; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Prevalence; Ribavirin; Risk Factors; RNA, Viral; Species Specificity | 2006 |
HIV and liver diseases: recent clinical advances.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Ribavirin | 2005 |
[The course of hepatitis C infection after liver transplantation].
Topics: Antiviral Agents; Genotype; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Treatment Outcome | 2005 |
New paradigms in the management of HIV and hepatitis C virus coinfection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
[HCV reinfection after liver transplantation for HCV cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Treatment Outcome | 2005 |
Viral hepatitis.
Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2006 |
HBV plus HCV, HCV plus HIV, HBV plus HIV.
Topics: Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Drug Interactions; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors | 2006 |
Novel approaches for therapy of chronic hepatitis C.
Topics: Antidepressive Agents; Antiviral Agents; Clinical Trials as Topic; Erythropoietin; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Protease Inhibitors; Purine-Nucleoside Phosphorylase; Pyrimidine Nucleosides; Ribavirin; Viral Hepatitis Vaccines | 2006 |
Review article: predicting response in hepatitis C virus therapy.
Topics: Antiviral Agents; Fibrosis; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Prognosis; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
[New trend in treatment in patients with chronic hepatitis C].
Topics: Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Lymphokines; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Treatment of interferon-alpha for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[HIV and HCV coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Contraindications; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Multicenter Studies as Topic; Patient Selection; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2006 |
Management of hepatitis C virus coinfection in HIV-infected persons.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2006 |
[HCV-HBV infection].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk | 2006 |
Treating hepatitis C infection in liver transplant recipients.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Reoperation; Ribavirin | 2006 |
Living donor liver transplantation to patients with hepatitis C virus cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Living Donors; Postoperative Complications; Recombinant Proteins; Ribavirin; Risk Factors; Secondary Prevention; Tissue and Organ Procurement | 2006 |
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention; Treatment Outcome | 2006 |
Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Case Management; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
[Treatment of hepatitis C in patients on renal replacement therapy].
Topics: Antiviral Agents; Cross Infection; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2007 |
Reversal of liver cirrhosis: a desirable clinical outcome and its pathogenic background.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Biopsy; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Management of chronic hepatitis C.
Topics: Antiviral Agents; Decision Trees; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2007 |
Therapeutic issues in HIV/HCV-coinfected patients.
Topics: Anemia; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Liver Transplantation; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Ribavirin; Transaminases | 2007 |
Hepatitis C virus infection in dialysis patients.
Topics: Antiviral Agents; Europe; Genome, Viral; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Japan; Liver Cirrhosis; Renal Dialysis; Ribavirin; RNA, Viral | 2007 |
[Treatment of recurrent hepatitis C virus infection after liver transplantation].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2007 |
Inflammation and repair in viral hepatitis C.
Topics: Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Risk Factors | 2008 |
Long-term effects of interferon-based therapy for chronic hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate; Treatment Outcome; Viral Load | 2007 |
[Review: clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
[Cryoglobulinemia].
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C; Humans; Immunologic Factors; Interferon-alpha; Liver Cirrhosis; Male; Recurrence; Ribavirin; Rituximab; Sex Factors; Vasculitis | 2008 |
Antiviral therapy for chronic hepatitis C viral infection.
Topics: Antiviral Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Liver Cirrhosis; Liver Neoplasms; Patient Selection; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral | 1995 |
Chronic hepatitis C.
Topics: Antiviral Agents; Blood Transfusion; Carcinoma, Hepatocellular; Cryoglobulinemia; Disease Progression; Forecasting; Genotype; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Porphyria Cutanea Tarda; Ribavirin; Risk Factors; Treatment Outcome | 1997 |
Therapy of hepatitis C: patients with cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Prognosis; Ribavirin; RNA, Viral | 1997 |
New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia.
Topics: Antiviral Agents; beta-Thalassemia; Child; Endocrine System Diseases; Female; Growth; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Osteoporosis; Pregnancy; Pregnancy Complications; Ribavirin; Sex Characteristics | 1998 |
Combination therapy for chronic hepatitis C: interferon and ribavirin.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Recurrence; Ribavirin | 1999 |
[Antiviral treatment of hepatitis C virus infection].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 1999 |
[Hepatitis C: natural history, biology, treatment monitoring].
Topics: Antiviral Agents; Biomarkers; France; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 1999 |
Advances in the treatment of hepatitis C.
Topics: Antiviral Agents; Biopsy; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Failure; Ribavirin | 2000 |
Recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Cytomegalovirus; Drug Therapy, Combination; Flaviviridae; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral | 2000 |
Treatment of chronic hepatitis C virus infection in patients with cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Ribavirin | 2000 |
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2000 |
A case of giant cell hepatitis recurring after liver transplantation and treated with ribavirin.
Topics: Adult; Antiviral Agents; Giant Cells; Hepatitis; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin | 2000 |
[Current treatment of chronic hepatitis B].
Topics: Antiviral Agents; Combined Modality Therapy; Contraindications; Hepatitis B, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; RNA, Viral | 2001 |
[Treatment of pretransplant and posttransplant viral cirrhosis].
Topics: Antiviral Agents; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Secondary Prevention; Virus Replication | 2001 |
Management of recurrent hepatitis C after liver transplantation.
Topics: Adrenal Cortex Hormones; Antiviral Agents; Cyclosporine; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Secondary Prevention; Tacrolimus | 2001 |
[Treatments for hepatitis virus C infections].
Topics: Amantadine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Prognosis; Ribavirin | 2001 |
Hepatitis C: a brief clinical overview.
Topics: Antiviral Agents; Black People; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Public Health; Remission, Spontaneous; Ribavirin | 2001 |
Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA | 2001 |
[PEG-interferons: significance for the treatment of viral hepatitis B and C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2001 |
[Present status of clinical trials on long-acting IFNs preparations (PEG-IFN alpha 2a, alpha 2b, IFN alpha-minipellet)].
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2001 |
[Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Cost-Benefit Analysis; Diagnosis, Differential; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2001 |
[HVB and HVC infections in nephrology].
Topics: Antiviral Agents; Comorbidity; Contraindications; Graft Rejection; Hepatitis B; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Lamivudine; Liver Cirrhosis; Postoperative Complications; Renal Dialysis; Ribavirin; Vaccination; Viral Hepatitis Vaccines; Viremia | 2001 |
[Treatment of chronic hepatitis C in cirrhosis of the liver].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2002 |
[Kidney transplantation in patients positive for hepatitis C virus].
Topics: Algorithms; Antiviral Agents; Cross Infection; Follow-Up Studies; Glomerulonephritis; Graft Survival; Hepatitis C; Humans; Interferons; Kidney Diseases; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Prevalence; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Survival Analysis; Tissue Donors; Treatment Outcome; Waiting Lists | 2002 |
185 trial(s) available for ribavirin and Cirrhosis, Liver
| Article | Year |
|---|---|
Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2023 |
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Immunologic Factors; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Patient-Centered Care; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2022 |
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Thalassemia; Treatment Failure; Uridine Monophosphate | 2017 |
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2,
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine | 2017 |
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Asia, Eastern; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Ribavirin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Time Factors | 2018 |
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Internationality; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Young Adult | 2018 |
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Topics: Adult; Aged; Antiviral Agents; Benzofurans; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sofosbuvir | 2018 |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2018 |
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult | 2018 |
Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.
Topics: Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Genotype; Hepatitis C; Humans; Interleukins; Liver; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Republic of Belarus; Ribavirin; Ritonavir; Russia; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2018 |
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2018 |
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Brazil; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.
Topics: Adult; Aged; Carbamates; Cohort Studies; Comorbidity; Female; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine | 2019 |
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Sofosbuvir for previously untreated chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Young Adult | 2013 |
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2013 |
Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Spleen; Splenectomy; Thrombocytopenia; Treatment Outcome | 2014 |
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse.
Topics: Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Thrombocytopenia; Treatment Outcome | 2014 |
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2014 |
Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Risk Factors; Viral Load | 2014 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; Sulfonamides; Valine | 2014 |
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Topics: Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Splenectomy; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Young Adult | 2014 |
Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Cholecalciferol; Dietary Supplements; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Prognosis; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Singapore; Treatment Outcome; Viral Load | 2015 |
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Topics: Compassionate Use Trials; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain | 2015 |
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists | 2015 |
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2015 |
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.
Topics: Adult; Case-Control Studies; China; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2014 |
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Topics: Acrylates; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Female; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Ribavirin; Thiazoles; Young Adult | 2015 |
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antiviral Agents; Biomarkers; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult | 2015 |
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine; Young Adult | 2015 |
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C
Topics: Adolescent; Adult; Aged; Antiviral Agents; Data Collection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Double-Blind Method; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebos; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Valine; Viral Load | 2015 |
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Young Adult | 2015 |
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2015 |
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2015 |
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypoalbuminemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Thrombocytopenia; Treatment Outcome; Uracil; Valine; Young Adult | 2015 |
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult | 2015 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2016 |
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Young Adult | 2015 |
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2016 |
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Gastroenterology; Genotype; Graft vs Host Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome; Viral Load; Young Adult | 2016 |
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Topics: Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure | 2016 |
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2016 |
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2016 |
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Young Adult | 2016 |
[Daclatasvir/sofosbuvir is effective also in advanced liver disease].
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans | 2017 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2016 |
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Topics: Adult; Antiviral Agents; Carbamates; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine | 2016 |
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Topics: Acrylates; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Prognosis; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Viral Load; Young Adult | 2016 |
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
Topics: Antiviral Agents; Bayes Theorem; Carbamates; Cohort Studies; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antiviral Agents; Diet; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Young Adult | 2008 |
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Topics: Adult; Albumins; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2009 |
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2009 |
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2009 |
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Topics: Adult; Amantadine; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Logistic Models; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Case-Control Studies; Demography; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Mutation; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2010 |
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2010 |
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Topics: Adult; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2010 |
[Clinical significance of leukopenia and neutropenia patients with chronic hepatitis "C" in the various regimes antiretroviral therapy].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Male; Middle Aged; Moscow; Neutropenia; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2010 |
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
Topics: Adult; Alanine Transaminase; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biomarkers; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Prevalence; Ribavirin; Severity of Illness Index; Vitamin D; Vitamin D Deficiency | 2011 |
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
Topics: Antiviral Agents; Biomarkers; Chi-Square Distribution; Coffee; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load | 2011 |
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Europe, Eastern; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2011 |
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2011 |
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
Topics: Antiviral Agents; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome | 2011 |
Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Longitudinal Studies; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2012 |
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
Topics: Adipokines; Adult; Chitinase-3-Like Protein 1; Disease Progression; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin | 2012 |
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thiazolidinediones; Treatment Outcome | 2012 |
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
Topics: Adolescent; Antiviral Agents; Body Composition; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Eating; Fatty Liver; Female; Growth Disorders; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
[Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Ribavirin; Splenectomy; Treatment Outcome | 2012 |
Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
Topics: Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Induction Chemotherapy; Interferon-alpha; Kidney; Liver Cirrhosis; Liver Transplantation; Logistic Models; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome; Viral Load | 2012 |
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Models, Biological; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Viral Load | 2012 |
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Topics: Adult; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Internationality; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome | 2012 |
Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Severity of Illness Index; Thrombocytopenia; Time; Treatment Outcome | 2013 |
Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study.
Topics: Antiviral Agents; Coinfection; Depression; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin | 2012 |
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral | 2013 |
Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ki-1 Antigen; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Failure; Treatment Outcome | 2002 |
Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.
Topics: Adjuvants, Immunologic; Antiviral Agents; CD4-Positive T-Lymphocytes; CD40 Ligand; Cells, Cultured; Cytokines; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Lymphocyte Activation; Male; Middle Aged; Mitogens; Monocytes; Recurrence; Ribavirin; RNA, Viral; Viral Core Proteins | 2002 |
Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Remission Induction; Ribavirin | 2003 |
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Topics: Adult; Algorithms; Antiviral Agents; Biomarkers; Biopsy; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2003 |
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recombinant Proteins; Ribavirin; Secondary Prevention; Viral Load | 2003 |
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Belgium; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Netherlands; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2003 |
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure | 2004 |
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleolus Organizer Region; Prospective Studies; Ribavirin; Silver Staining | 2004 |
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2004 |
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2004 |
Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Epidermal Growth Factor; Female; Growth Substances; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet-Derived Growth Factor; Prognosis; Recombinant Proteins; Ribavirin | 2005 |
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2005 |
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
[Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin | 2005 |
Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Topics: Adult; Aged; Biopsy; Cohort Studies; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2006 |
Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2006 |
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors | 2006 |
Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.
Topics: Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Schistosoma; Schistosomiasis; Treatment Outcome | 2006 |
Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatic Veins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viremia | 2006 |
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2007 |
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2006 |
Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation; Antiviral Agents; CTLA-4 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Characteristics; T-Lymphocytes; Treatment Outcome | 2007 |
Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention | 2007 |
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Health Status; Health Surveys; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 2007 |
Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome; United States | 2007 |
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2007 |
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Diabetes Mellitus; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2007 |
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Darbepoetin alfa; Disease Progression; Dose-Response Relationship, Drug; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin; Secondary Prevention | 2007 |
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Ribavirin | 2007 |
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.
Topics: Adolescent; Adult; Age Factors; Aged; Diabetes Complications; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Refusal; Viral Load | 2007 |
Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; Serologic Tests; Time Factors; Treatment Outcome | 2007 |
Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Syria; Treatment Outcome; Viral Load | 2008 |
Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2008 |
The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2008 |
[Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
Topics: Actins; Adult; Antiviral Agents; Collagen Type III; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Liver; Liver Cirrhosis; Male; Middle Aged; Muscle, Smooth; Ribavirin; Treatment Outcome | 2008 |
Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1998 |
Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome | 1999 |
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 1999 |
Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2000 |
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha | 2002 |
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
679 other study(ies) available for ribavirin and Cirrhosis, Liver
| Article | Year |
|---|---|
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine | 2021 |
Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2021 |
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferons; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Seoul; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2022 |
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2022 |
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Organ Transplantation; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate | 2022 |
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Mechanisms of CD8+ T-cell failure in chronic hepatitis E virus infection.
Topics: CD8-Positive T-Lymphocytes; Epitopes, T-Lymphocyte; Hepatitis E; Hepatitis E virus; Humans; Interferon-gamma; Liver Cirrhosis; Liver Failure; Ribavirin | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Prospective Studies; Ribavirin; Ritonavir; Romania; Sulfonamides; Uracil; Valine | 2022 |
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort.
Topics: Aged; Antiviral Agents; Brazil; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Effectiveness of Direct-acting Agents After Liver Transplantation A Real-life Study in Rio de Janeiro.
Topics: Antiviral Agents; Aspartic Acid; Biomarkers; Brazil; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA; Transaminases | 2022 |
Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis.
Topics: Adult; Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin | 2023 |
Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2023 |
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2023 |
Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
Topics: Antiviral Agents; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Liver Cirrhosis; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2023 |
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome | 2023 |
How do we treat psoriasis patients with hepatitis C infections in real-world situations? A retrospective analysis of 34 patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Psoriasis; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2021 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipase; Liver; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral | 2019 |
The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Common Variable Immunodeficiency; Drug Therapy, Combination; Fatal Outcome; Focal Nodular Hyperplasia; Hepatitis E; Hepatitis E virus; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir | 2020 |
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Lost to Follow-Up; Male; Middle Aged; National Health Programs; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
Topics: Antiviral Agents; Cytokines; Fatty Acid-Binding Proteins; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2020 |
Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Thailand; Time Factors; Treatment Outcome; Uridine Monophosphate | 2020 |
Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin | 2021 |
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Valine | 2020 |
Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Aged, 80 and over; Female; Hepatitis E; Humans; Immunocompromised Host; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Scotland | 2020 |
Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin | 2020 |
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine | 2020 |
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Topics: Adult; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Carbamates; Drug Combinations; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Glycosylation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; ROC Curve; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Genotype; Glycosylation; Hepacivirus; Hepatitis C; Humans; Immunoglobulin G; Interferon alpha-2; Liver Cirrhosis; Middle Aged; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Load; Young Adult | 2020 |
Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; ROC Curve; South Africa; Sustained Virologic Response; Tertiary Care Centers | 2020 |
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Romania; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2020 |
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Infant, Newborn; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine | 2021 |
Ribavirin monotherapy for the treatment of chronic hepatitis E in an immunosuppressed patient.
Topics: Antiviral Agents; Hepatitis E; HIV Infections; Humans; Immunocompromised Host; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2021 |
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Sofosbuvir | 2020 |
A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Topics: Aged; Antiviral Agents; Brazil; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Transplant Recipients; Treatment Outcome | 2021 |
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins | 2021 |
Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
THE ROLE OF GALECTIN-9 IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND ITS CONNECTION WITH THE TYPE OF THERAPY, THE DEGREE OF FIBROSIS, CLINICAL, LABORATORY, AUTOIMMUNE AND INTEGRATIVE INDICATORS.
Topics: Galectins; Hepatitis C, Chronic; Humans; Laboratories; Liver Cirrhosis; Ribavirin | 2021 |
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2017 |
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
Topics: Adult; Antiviral Agents; Asia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA Viruses; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
Topics: Aged; Anemia; Antiviral Agents; California; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Sex Factors; Sofosbuvir; Viral Load | 2017 |
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Propensity Score; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Simeprevir; Sofosbuvir; Valine | 2017 |
Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2017 |
PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PREDICTORS OF THE EFFECTIVENESS OF PEGYLATED INTERFERON IN PATIENTS WITH HEPATITIS C IN GEORGIA.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Georgia (Republic); Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult | 2017 |
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation-Authors' reply.
Topics: Antiviral Agents; Child; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation.
Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Noninvasive serum models to predict significant liver related events in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin | 2017 |
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2017 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Topics: 2-Naphthylamine; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Period; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
Topics: Aged; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Egypt; Female; Glycated Hemoglobin; Glycemic Index; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2017 |
Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.
Topics: Adult; Age Factors; Antiviral Agents; China; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Fees, Pharmaceutical; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Ribavirin; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Young Adult | 2017 |
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Analysis of Hepatitis C Virus NS5A Region in Patients with Cirrhosis Using an Ultra-Deep Pyrosequencing Method.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation; Ribavirin; Viral Nonstructural Proteins | 2017 |
Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Compassionate Use Trials; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Waiting Lists | 2018 |
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2017 |
Chronic hepatitis E virus infection in a cirrhotic patient: A case report.
Topics: Antiviral Agents; Enzyme-Linked Immunospot Assay; Hepatitis E; Hepatitis, Chronic; Humans; Interferon-gamma; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2017 |
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
Topics: Adult; Age Factors; Antiviral Agents; Cold Ischemia; Drug Therapy, Combination; Female; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Warm Ischemia; Young Adult | 2017 |
Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Mental Health; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome | 2018 |
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir | 2018 |
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine | 2017 |
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2017 |
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Topics: Aged; Antiviral Agents; Austria; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Ribavirin; Sustained Virologic Response | 2018 |
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine | 2018 |
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine | 2018 |
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan; Tomography, X-Ray Computed; Treatment Failure | 2018 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Saudi Arabia; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Reply to: "'Who killed JR': Chronic hepatitis C or alcohol use disorders?"
Topics: Alcoholism; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2018 |
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load | 2018 |
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Spain; Treatment Outcome; Young Adult | 2018 |
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Diabetes Complications; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Uridine Monophosphate | 2018 |
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate | 2018 |
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2018 |
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2018 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Ritonavir; Sofosbuvir; Treatment Outcome | 2018 |
Editorial: retreatment of DAA-failures-no problem at all?
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir | 2018 |
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2019 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine | 2018 |
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2018 |
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
Topics: Administration, Oral; Adult; Carbamates; Case-Control Studies; Drug Combinations; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2020 |
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Findings from a large Asian chronic hepatitis C real-life study.
Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2018 |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Taiwan | 2018 |
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Valine | 2019 |
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Users; Female; Genotype; Georgia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous | 2018 |
Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Female; gamma-Globulins; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Imidazoles; Liver; Liver Cirrhosis; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Serum Albumin; Sofosbuvir; Valine; Viral Load | 2019 |
Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load | 2019 |
Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response; Taiwan | 2019 |
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2019 |
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir | 2019 |
Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response | 2019 |
Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Obesity; Prospective Studies; Ribavirin; Risk Factors; Sex Factors | 2019 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine | 2019 |
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2019 |
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2022 |
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Utility of viral kinetics in HCV therapy - It is not over until it is over?
Topics: Duration of Therapy; Hepacivirus; Hepatitis C; Humans; Kinetics; Liver Cirrhosis; Ribavirin | 2019 |
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis E; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Ribavirin; Sofosbuvir | 2019 |
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclopropanes; Hepatectomy; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Middle Aged; Neoplasm Recurrence, Local; Proline; Prospective Studies; Radiofrequency Ablation; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
Cluster of hepatitis C in a family: a twenty-year follow-up.
Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Family; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Needle Sharing; Ribavirin | 2019 |
Follow-up Results of
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2019 |
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
Topics: Antiviral Agents; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Treatment Outcome; Virus Activation | 2013 |
Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Pancreatitis; Panniculitis; Ribavirin; Skin | 2013 |
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2013 |
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Cardiovascular Diseases; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Practice Guidelines as Topic; Ribavirin; Young Adult | 2013 |
Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients.
Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Cohort Studies; Cross-Sectional Studies; Egypt; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Sex Factors; Viral Load | 2013 |
Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin.
Topics: Antiviral Agents; Hepatitis E; Hepatitis, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome | 2013 |
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Topics: Antiviral Agents; Chromatography, Liquid; Drug Monitoring; Hepacivirus; Hepatitis; Humans; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Tandem Mass Spectrometry | 2013 |
Combination therapy of low-dose of PegIFNa-2a and ribavirin for patients with HCV-infected decompensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy | 2013 |
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Praziquantel; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Schistosomiasis; Schistosomicides; Time Factors; Treatment Outcome | 2013 |
Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2014 |
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Thrombocytopenia; Young Adult | 2013 |
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Blood Coagulation Disorders; Blood Transfusion; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Transfusion Reaction; Young Adult | 2013 |
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
Topics: Adult; Age Factors; Antiviral Agents; Blood Platelets; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2013 |
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Poisson Distribution; Prospective Studies; Ribavirin | 2013 |
Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Disease Progression; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral | 2014 |
Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Fatigue; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Mental Health; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
Liver histology of chronic hepatitis C patients who relapsed or not responded to conventional interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Treatment Failure | 2013 |
Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.
Topics: Adult; Antiviral Agents; Bangladesh; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2013 |
Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders.
Topics: Adult; Aged; Biopsy; Cross-Sectional Studies; Fatty Liver; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Failure; Ultrasonography; Young Adult | 2013 |
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Ascites; Disease Progression; Female; Follow-Up Studies; Hemorrhage; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Withholding Treatment | 2013 |
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2013 |
Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Ribavirin; Risk Assessment; Risk Factors; Time Factors | 2013 |
Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C.
Topics: Antiviral Agents; Asthenia; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Viral Load | 2013 |
Treatment of chronic hepatitis C in injecting drug users--a 5-year follow-up.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Recurrence; Ribavirin; Serbia; Substance Abuse, Intravenous; Treatment Outcome | 2013 |
Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Incidence; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2013 |
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Topics: Anemia; Diabetes Mellitus, Type 2; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Statistics, Nonparametric | 2014 |
[Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy].
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Postoperative Period; Ribavirin; Splenectomy; Treatment Outcome | 2013 |
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.
Topics: Carrier State; Genotype; Hepatitis C; Humans; Interferon Regulatory Factor-3; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Muscle Proteins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Recombinant Proteins; Ribavirin | 2014 |
Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2014 |
Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Severity of Illness Index; Young Adult | 2013 |
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 2014 |
Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve; Viral Load | 2013 |
Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Retrospective Studies; Ribavirin; Young Adult | 2014 |
Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C.
Topics: Adult; Animals; Antimicrobial Cationic Peptides; Antiviral Agents; Epidermal Growth Factor; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocyte Growth Factor; Hepcidins; Humans; Interferon-alpha; Iron; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Phlebotomy; Renal Insufficiency, Chronic; Ribavirin; Virus Replication | 2014 |
Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Treatment of decompensated cirrhosis secondary to hepatitis C with antiviral therapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin | 2014 |
Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Regulatory Factors; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Metallothionein; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation; Viral Load | 2014 |
Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome | 2014 |
Telaprevir use in a chronic hepatitis C patient with hemophilia.
Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome | 2014 |
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Commentary: real-world triple therapy experience treating hepatitis C virus.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2014 |
Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2014 |
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
Topics: Adult; Antiviral Agents; Decision Support Techniques; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Middle Aged; Models, Statistical; Prognosis; Ribavirin; Risk Assessment; Severity of Illness Index | 2014 |
3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Esters; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphorus; Ribavirin; Time Factors; Treatment Outcome | 2014 |
Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Risk Factors; Taiwan | 2014 |
[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Topics: Algorithms; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Early Diagnosis; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C; Humans; Hungary; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2014 |
[MUW researcher of the month].
Topics: Austria; Awards and Prizes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; History, 21st Century; HIV Seropositivity; Humans; Interferons; Interleukins; Liver Cirrhosis; Precision Medicine; Ribavirin; Translational Research, Biomedical | 2014 |
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome | 2014 |
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Severity of Illness Index | 2014 |
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Liver Cirrhosis; MicroRNAs; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Statistics, Nonparametric; Viral Load | 2014 |
Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Epistaxis; Esophageal and Gastric Varices; Feasibility Studies; Female; Gastrointestinal Hemorrhage; Gingival Hemorrhage; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia | 2014 |
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Liver Cirrhosis; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Retreatment; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
De novo autoimmune hepatitis after interferon treatment in a liver transplant recipient with common variable immunodeficiency.
Topics: Antiviral Agents; Common Variable Immunodeficiency; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Ribavirin; Young Adult | 2014 |
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2014 |
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
[Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cholesterol; Drug Therapy, Combination; False Positive Reactions; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Hypertriglyceridemia; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load; Viremia | 2015 |
Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Topics: Antiviral Agents; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost of Illness; End Stage Liver Disease; England; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenectomy; Treatment Outcome | 2015 |
Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Topics: Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Biomarkers; Biopsy; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome; Viral Load | 2015 |
[Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Topics: Adult; Aged; Antiviral Agents; Cellulitis; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Parotitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sepsis; Staphylococcal Infections; Treatment Outcome; Withholding Treatment | 2015 |
Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.
Topics: Adult; Aged; Amino Acids; Animals; Antiviral Agents; Cell Line, Tumor; Dietary Supplements; Drug Therapy, Combination; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Middle Aged; Multiprotein Complexes; Nutritional Status; Proto-Oncogene Proteins c-jun; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; TOR Serine-Threonine Kinases; Transforming Growth Factor beta | 2014 |
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
[Treatment of recurrent HCV infection after liver transplantation].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2013 |
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin; Survival Analysis; Viral Load | 2015 |
Consensus guidelines for the management of hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Saudi Arabia | 2003 |
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Predictive Value of Tests; Ribavirin; RNA, Viral; Viral Load | 2014 |
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Recurrence; Retrospective Studies; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Virus Activation | 2015 |
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Protective Factors; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.
Topics: Autophagy; Biological Transport; Biopsy; Cells, Cultured; Down-Regulation; Endoplasmic Reticulum Stress; Ethanol; Fatty Acids, Nonesterified; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Liver; Liver Cirrhosis; Receptor, Interferon alpha-beta; Receptors, Interferon; Ribavirin; Virus Replication | 2014 |
[Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
Topics: Anemia; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Oligopeptides; Polyethylene Glycols; Prevalence; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; Spain | 2014 |
Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Remission Induction; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Waiting Lists | 2015 |
Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load | 2014 |
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
New kids on the block--step by step to an ideal HCV therapy.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides | 2015 |
Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2015 |
Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2014 |
Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description.
Topics: Anemia; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Erythropoietin; Glomerulonephritis, Membranoproliferative; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
[Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA; Viral Load | 2015 |
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
PHOTON-2: hope for patients with HIV and HCV co-infection?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2015 |
[Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Russia; Simeprevir; Sulfonamides | 2014 |
[New combination therapy increases chances of recovery].
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Sex Factors; Thrombocytopenia; Treatment Outcome | 2015 |
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Proline; Prospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2015 |
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.
Topics: Adult; Age Factors; Antiviral Agents; Diabetes Mellitus, Type 2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome | 2015 |
Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Leukocyte Count; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Splenectomy; Survival Rate; Thrombocytopenia; Viral Load | 2015 |
High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2015 |
Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Hepatic progenitor cells in children with chronic hepatitis C: correlation with histopathology, viremia, and treatment response.
Topics: Adolescent; Antiviral Agents; Cell Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Stem Cells; Treatment Outcome; Viral Load | 2015 |
Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin | 2015 |
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recurrence; Reoperation; Ribavirin; Sofosbuvir | 2015 |
Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load | 2015 |
Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
Topics: Aged; Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Tacrolimus; Treatment Outcome | 2015 |
IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Ribavirin; ROC Curve; Treatment Outcome; Viral Load; Young Adult | 2015 |
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Topics: Antiviral Agents; Clinical Decision-Making; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Spain; Treatment Outcome; Viral Load; Viremia | 2015 |
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
Topics: Aged; Analysis of Variance; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Safety; Reference Values; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
[Editorial commentary: Hepatitis C].
Topics: Antiviral Agents; Congresses as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Hungary; Interferons; Liver Cirrhosis; Protease Inhibitors; Research Report; Ribavirin | 2015 |
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Treatment Outcome; Viral Load | 2015 |
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Topics: Aged; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Japan; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.
Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2015 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Topics: Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans | 2015 |
Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholestasis, Intrahepatic; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Matched-Pair Analysis; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; Time Factors; Treatment Outcome; White People; Young Adult | 2014 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?
Topics: Aged; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Ribavirin; Surveys and Questionnaires; White People | 2016 |
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Republic of Korea; Ribavirin; Young Adult | 2016 |
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate | 2015 |
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Random Allocation; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2015 |
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Topics: Antiviral Agents; Asia; Asian People; Australia; Biomarkers; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proline; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load; White People | 2015 |
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine | 2015 |
Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Black or African American; Chemokine CXCL1; Chemokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-8; Interleukins; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; White People; Young Adult | 2015 |
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Texas; Time Factors; Treatment Outcome | 2016 |
Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Signal Transduction; Thailand; Treatment Outcome | 2015 |
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2016 |
Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin; Risk Factors | 2016 |
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mutation; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
Topics: Antiviral Agents; Coinfection; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2015 |
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Carriers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Oligopeptides; Patient Acuity; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
[Kinetics of Virus Load HCV-RNA in Blood Serum and Peripheral Mononuclear Cells in a Patient with Hepatocirrhosis and Chronic Virus Hepatitis C Termination Treated According to Noninterferon Treatment Scheme (Cycloferon + Ribavirin)].
Topics: Acridines; Antiviral Agents; Contraindications; Drug Substitution; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Inducers; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Viral Load | 2015 |
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?
Topics: Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir | 2015 |
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
[Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Ribavirin; Uridine Monophosphate | 2015 |
[Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
Topics: Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome | 2016 |
Hepatitis C treatment at three Norwegian hospitals 2000-2011.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Norway; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2015 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
Topics: Acidosis, Lactic; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Oligopeptides; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome | 2016 |
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2015 |
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Coinfection; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukin-15; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Viral Load | 2016 |
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Polymorphism, Genetic; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2017 |
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Veterans | 2016 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2016 |
Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
Topics: Adult; Antiviral Agents; Canada; Cohort Studies; Coinfection; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Practice Guidelines as Topic; Republic of Korea; Ribavirin | 2016 |
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
Topics: Adult; Antiviral Agents; beta-Thalassemia; Drug Therapy, Combination; Female; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Italy; Liver Cirrhosis; Logistic Models; Male; Multivariate Analysis; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2016 |
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.
Topics: Aged; Antiviral Agents; Esophageal and Gastric Varices; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Hypertension, Portal; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; Sustained Virologic Response | 2016 |
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply.
Topics: Bilirubin; Gilbert Disease; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2016 |
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir?
Topics: Bilirubin; Gilbert Disease; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2016 |
Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
Topics: Anemia, Hemolytic; Antiviral Agents; Bacteremia; Blood Component Transfusion; Catheter-Related Infections; Drug Therapy, Combination; Glomerulonephritis; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Renal Dialysis; Ribavirin; Staphylococcal Infections; Thrombocytopenia | 2017 |
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Proportional Hazards Models; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Ultrasonography | 2016 |
Persisting hepatitis E virus infection leading to liver cirrhosis despite recovery of the immune system in an HIV-infected patient.
Topics: Antiviral Agents; DNA, Viral; Hepatitis E; Hepatitis E virus; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2016 |
Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.
Topics: Adult; Cohort Studies; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Ribavirin; United States; United States Department of Veterans Affairs | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sustained Virologic Response; Time | 2016 |
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Remission Induction; Retrospective Studies; Ribavirin; ROC Curve; Severity of Illness Index; Sustained Virologic Response; Time Factors; Treatment Outcome | 2016 |
Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Peptidyl-Dipeptidase A; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Young Adult | 2016 |
[THE USE OF COMBINATION ANTIVIRAL THERAPY IN LIVER CIRRHOSIS HCV ETIOLOGY].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2015 |
Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats.
Topics: Animals; Antiviral Agents; Blotting, Western; Carbon Tetrachloride; Drug Synergism; Drug Therapy, Combination; Helianthus; Immunoenzyme Techniques; Interferon-alpha; Liver Cirrhosis; Male; Plant Extracts; Polyethylene Glycols; Rats; Recombinant Proteins; Ribavirin | 2016 |
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome | 2016 |
Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.
Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Tertiary Care Centers | 2016 |
IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.
Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2016 |
Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.
Topics: Benzimidazoles; Cryoglobulinemia; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2016 |
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Topics: Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2017 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Drug Therapy, Combination; Egypt; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; International Normalized Ratio; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
From current status to optimization of HCV treatment: Recommendations from an expert panel.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies, Medical; Viral Load | 2016 |
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; England; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Ribavirin; Treatment Outcome | 2016 |
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Dysbiosis; Female; Hepacivirus; Hepatitis C; Humans; Inflammation; Interferons; Liver Cirrhosis; Male; Microbiota; Middle Aged; Outpatients; Ribavirin | 2016 |
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2017 |
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prospective Studies; Registries; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult | 2017 |
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Longitudinal Studies; Male; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2016 |
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans | 2016 |
Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult | 2016 |
von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.
Topics: Adult; Antiviral Agents; Austria; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Regression Analysis; Retrospective Studies; Ribavirin; ROC Curve; von Willebrand Factor | 2016 |
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Topics: Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Models, Economic; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate | 2017 |
Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
Topics: Aged; Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Female; France; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
[PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Topics: Adult; Antiviral Agents; Blood Group Antigens; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Recombinant Proteins; Reproducibility of Results; Ribavirin | 2016 |
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Topics: Aged; Antiviral Agents; Aspartate Aminotransferases; Blood Platelets; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan | 2016 |
Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Proline; Quality of Life; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Bilirubin; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ribavirin; Risk Factors; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Failure; Uridine Monophosphate; Young Adult | 2016 |
Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy.
Topics: Abdomen; Antiviral Agents; Drug Therapy, Combination; Endoscopy, Digestive System; Esophageal and Gastric Varices; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenomegaly; Tomography, X-Ray Computed; Ultrasonography | 2016 |
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photosensitivity Disorders; Porphyrins; Recurrence; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Republic of Korea; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response | 2016 |
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States | 2016 |
Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded.
Topics: Genotype; Hepacivirus; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Veterans | 2017 |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Failure; Treatment Outcome | 2016 |
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Topics: Administration, Oral; Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir | 2017 |
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Decision Making; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Markov Chains; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate | 2017 |
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome | 2017 |
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hong Kong; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Models, Economic; Postoperative Care; Preoperative Care; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2017 |
Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.
Topics: Administration, Oral; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Treatment Outcome | 2016 |
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2017 |
Treatment of Patients with Cirrhosis.
Topics: Antiviral Agents; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2016 |
Treatment of Patients with Cirrhosis.
Topics: Antiviral Agents; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2016 |
Treatment of Patients with Cirrhosis.
Topics: Antiviral Agents; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2016 |
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombination, Genetic; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult | 2017 |
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sulfonamides; Taiwan; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors | 2017 |
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2017 |
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin | 2017 |
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
Topics: Alanine Transaminase; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Middle Aged; Phylogeny; Reassortant Viruses; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Failure | 2017 |
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Belgium; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2017 |
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
Topics: Aged; Alleles; Anemia; Antiviral Agents; Disease Susceptibility; Drug Therapy, Combination; Enzyme Activation; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Liver Cirrhosis; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Risk Factors; Severity of Illness Index | 2017 |
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Topics: Antiviral Agents; Benzimidazoles; China; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Medical Tourism; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Therapeutic Equivalency; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2017 |
Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Ribavirin; Serum Albumin; Treatment Outcome | 2017 |
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.
Topics: Aged; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Ribavirin; Treatment Outcome | 2009 |
Late occurrence of pleural and peritoneal effusion due to Mycobacterium tuberculosis infection (TB) in a patient with posttransplantation recurrent HCV chronic hepatitis: safety of peginterferon and ribavirin treatment after recovery of TB:- a case report
Topics: Adult; Antiviral Agents; Ascitic Fluid; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Mycobacterium tuberculosis; Pleural Effusion; Postoperative Complications; Ribavirin; Safety; Treatment Outcome; Tuberculosis | 2008 |
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2008 |
Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Young Adult | 2008 |
Factors influencing the participation of gastroenterologists and hepatologists in clinical research.
Topics: Adult; Aged; Antiviral Agents; Attitude of Health Personnel; Biomedical Research; Clinical Competence; Clinical Trials as Topic; Costs and Cost Analysis; Drug Industry; Ethnicity; Evidence-Based Medicine; Female; Gastroenterology; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Physicians; Research Support as Topic; Ribavirin; Surveys and Questionnaires; United States | 2008 |
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
[HIV and hepatitis C coinfection].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load | 2008 |
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Ribavirin; Secondary Prevention; Treatment Outcome; Young Adult | 2008 |
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2009 |
Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Case-Control Studies; Diabetes Mellitus; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Ohio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Failure; Viral Load | 2009 |
Changes of non-invasive markers and FibroScan values during HCV treatment.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2009 |
Jaundice developing in a patient with hepatitis C4 months after liver transplantation.
Topics: Antiviral Agents; Fatal Outcome; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Jaundice; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Tacrolimus | 2009 |
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Viral Load | 2008 |
Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
Topics: Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Plasma; Polyethylene Glycols; Recombinant Proteins; Retinol-Binding Proteins, Plasma; Ribavirin; Severity of Illness Index; Viral Load | 2009 |
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Body Mass Index; Cholesterol, HDL; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Diagnosis, management, and treatment of hepatitis C: an update.
Topics: Biopsy; Counseling; Drug Users; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2009 |
High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Romania; Severity of Illness Index; Time Factors; Transaminases; Treatment Outcome; Viral Load | 2009 |
[ANRS HC 02 RIBAVIC: histo-pathological impact].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
[ANRS HC 02 RIBAVIC: from multicenter trial to daily practice. Conclusions].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Multicenter Studies as Topic; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Treatment for recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biopsy; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2009 |
Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2009 |
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2009 |
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Asian People; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2009 |
Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Treatment Failure; Viral Load | 2009 |
[Spontaneous and treatment-induced virological dynamic in the plasma, PBMC and liver tissue in a patient with chronic HBV and HCV coinfection].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2009 |
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Cohort Studies; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2009 |
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.
Topics: Adult; Antiviral Agents; Black People; Egypt; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Laparoscopy; Length of Stay; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Splenectomy; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2010 |
An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
[A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin | 2009 |
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression.
Topics: Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Ribavirin | 2010 |
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
[Treatment for chronic hepatitis C, more opportunity, more challenge].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Female; Gene Frequency; Haplotypes; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Taiwan; Treatment Outcome; Viral Load | 2010 |
Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Up-Regulation | 2010 |
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Cholestanetriol 26-Monooxygenase; Cytochrome P450 Family 2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Vitamin D | 2010 |
Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Serum; Severity of Illness Index; Treatment Outcome; Vitamin B 12 | 2011 |
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Treatment of cirrhotics].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
Treating hepatitis C in patients with cirrhosis: the effort is worth it.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; Treatment Outcome | 2010 |
Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.
Topics: Adult; Alcohol Drinking; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Socioeconomic Factors; Switzerland; Treatment Outcome; Viral Load | 2010 |
[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2010 |
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Spain; Treatment Outcome | 2010 |
Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
Topics: Adult; Antigens, CD; Antigens, CD19; Antiviral Agents; B-Lymphocyte Subsets; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tetraspanin 28 | 2011 |
Hepatitis C treatment response kinetics and impact of baseline predictors.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2011 |
An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Topics: Antiviral Agents; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Markov Chains; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Middle Aged; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.
Topics: Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Severity of Illness Index; Taiwan; Time Factors; Treatment Outcome; Viral Load | 2010 |
Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus.
Topics: Adult; Aged; Algorithms; Antiviral Agents; Area Under Curve; Chemokine CXCL10; Extracellular Matrix Proteins; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Transforming Growth Factor beta; Treatment Outcome; Viral Load | 2010 |
Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
Topics: Adult; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Biopsy; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin | 2009 |
Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2010 |
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Chronic hepatitis C treatment in näive patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Clinical Enzyme Tests; Drug Therapy, Combination; Hepatitis, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Practice Guidelines as Topic; Predictive Value of Tests; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome | 2010 |
How sustained is sustained viral response in patients with hepatitis C virus infection?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Tables; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2010 |
Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
Topics: Adult; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Macrophage-dominant sialadenitis in human T-cell leukemia virus type I-associated myelopathy after living-donor liver transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Humans; Immunoglobulin G; Leukemia-Lymphoma, Adult T-Cell; Liver Cirrhosis; Liver Transplantation; Living Donors; Macrophages; Male; Middle Aged; Ribavirin; Sialadenitis | 2010 |
Early diagnosis and treatment resolved cholestatic hepatitis C without fibrosis after living donor liver transplantation: report of a case.
Topics: Antiviral Agents; Biopsy; Cholangiography; Cholestasis, Intrahepatic; Diagnosis, Differential; Drug Carriers; Early Diagnosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; RNA, Viral; Ultrasonography, Doppler | 2010 |
Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Romania; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
The smoldering epidemic. The number of new cases of hepatitis C is down, but millions are chronically infected and may not know it.
Topics: Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2010 |
Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Cohort Studies; Denmark; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Epidemiologic Methods; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Young Adult | 2011 |
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
Topics: Adult; Age Distribution; Comorbidity; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Schistosomiasis; Transaminases; Treatment Outcome | 2011 |
A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asia; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; Humans; Infant; Interferon-beta; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome | 2011 |
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tissue Donors; Treatment Outcome | 2011 |
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Envelope Proteins; Viral Load; Virus Activation | 2011 |
Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA Splice Sites; Treatment Outcome; Young Adult | 2011 |
Consensus interferon: tailored therapy and the impact of adherence.
Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Consensus Sequence; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Sustained virologic response decreases serum markers of angiogenesis, inflammation, and fibrosis in HIV/HCV-coinfected patients on hepatitis C virus therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neovascularization, Pathologic; Retrospective Studies; Ribavirin | 2011 |
[A case with chronic hepatitis C who developed liver cirrhosis due to liver dysfunction caused by pegylated interferon plus ribavirin treatment despite negativity of serum HCV RNA, during therapy].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2011 |
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Topics: Adult; Analysis of Variance; Antiviral Agents; Biomarkers; Biopsy; Case-Control Studies; Chi-Square Distribution; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Nicotinamide Phosphoribosyltransferase; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Taiwan; Treatment Outcome; Up-Regulation; Viral Load | 2011 |
A laparoscopic splenectomy allows the induction of antiviral therapy for patients with cirrhosis associated with hepatitis C virus.
Topics: Aged; Antiviral Agents; Blood Loss, Surgical; Contraindications; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Length of Stay; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenectomy; Thrombocytopenia | 2011 |
Five-year follow-up of patients with chronic C hepatitis and sustained virological response.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2011 |
Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.
Topics: Adult; Aging; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin | 2011 |
[Evaluation of selected laboratory markers of liver fibrosis in patients with chronic hepatitis type C].
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Biopsy; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Platelet Count; Ribavirin | 2010 |
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Portal Pressure; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome | 2011 |
Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Systemic Vasculitis; Treatment Outcome | 2011 |
[Metabolic syndrome in patients with chronic hepatitis C genotype 1].
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Leptin; Liver Cirrhosis; Male; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2011 |
Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Drug Therapy, Combination; Hepatic Stellate Cells; Interferons; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Rats; Ribavirin; Vascular Endothelial Growth Factor A | 2011 |
Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Cell Line, Tumor; Drug Therapy, Combination; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver; Liver Cirrhosis; Male; Malnutrition; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Molecular Sequence Data; Multiprotein Complexes; Nutritional Status; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Proteins; Recombinant Proteins; Regression Analysis; Ribavirin; RNA Interference; RNA, Viral; Severity of Illness Index; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; TOR Serine-Threonine Kinases; Transaminases; Transfection; Treatment Outcome; Viral Load; Virus Replication | 2011 |
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
Topics: Adult; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2011 |
[Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral | 2011 |
Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Body Mass Index; Dyspnea; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Spirometry; Young Adult | 2011 |
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Ribavirin | 2011 |
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Alcohol Drinking; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2011 |
Treatment of glomerulonephritis associated with hepatitis C virus in patient with cirrhosis: only pegylated interferon and ribavirin.
Topics: Antiviral Agents; Glomerulonephritis; Hepacivirus; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2011 |
Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Mutation; Patient Selection; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins | 2011 |
Liver stiffness diminishes with antiviral response in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome | 2011 |
Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Hand-Assisted Laparoscopy; Hepatitis C; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Japan; Laparoscopy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2011 |
One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Fatty Liver; Female; Ferritins; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
Topics: Adult; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2012 |
Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2011 |
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
[Experience with ronkoleukin and alfaferon combination in complex chronic hepatitis C treatment].
Topics: Adult; Antigens, CD; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load | 2011 |
Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2012 |
The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Topics: Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
[Treatment of chronic hepatitis C virus infection. A study of best predictors for response].
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Young Adult | 2011 |
CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling.
Topics: Antiviral Agents; Biomarkers; Biopsy; Chemokine CCL5; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Leukocytes; Liver; Liver Cirrhosis; Microarray Analysis; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Signal Transduction; Toll-Like Receptor 3 | 2012 |
Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Romania; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Medication Adherence; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Risk Factors; Treatment Outcome | 2012 |
The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Ribavirin | 2012 |
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Ribavirin; Thrombocytopenia; Young Adult | 2012 |
Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Ribavirin | 2012 |
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lipase; Liver Cirrhosis; Logistic Models; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].
Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load | 2012 |
Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Homozygote; Humans; Interferon-alpha; Lipoproteins, LDL; Liver Cirrhosis; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2012 |
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
Topics: Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Biomarkers; Drug Monitoring; Female; Hepacivirus; Hepatic Insufficiency; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Rituximab; Treatment Outcome; Viral Load | 2012 |
Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2012 |
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Viral Load | 2012 |
New approaches to the management of hepatitis C in haemophilia in 2012.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
[Efficacy of peg interferon alpha-2a in combination with ribavirin in treatment of with hepatitis C cirrhosis patients].
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Predicted effects of treatment for HCV infection vary among European countries.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Mass Screening; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2012 |
Expression of IFNAR2 mRNA in peripheral blood mononuclear cells of patients with HCV infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; RNA, Messenger | 2012 |
Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Platelet Count; Receptors, Fc; Recombinant Fusion Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Thrombopoietin; Time Factors; Treatment Outcome | 2012 |
Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; HLA-B15 Antigen; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA | 2012 |
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Topics: Adult; Anti-Retroviral Agents; Cardiac Output; CD4 Lymphocyte Count; Coinfection; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Interferon-alpha; Liver; Liver Cirrhosis; Lung; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viremia | 2012 |
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load | 2012 |
YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
Topics: Adipokines; Adult; Antiviral Agents; Chitinase-3-Like Protein 1; Cyclosporine; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lectins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Factors; Statistics, Nonparametric; Tacrolimus; Time Factors; Young Adult | 2013 |
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors | 2013 |
IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Platelet Count; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Viral Load | 2012 |
SASLT practice guidelines: management of hepatitis C virus infection.
Topics: Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors; Saudi Arabia | 2012 |
Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
Topics: Adult; Aged; Anticarcinogenic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2013 |
The effect of unsuccessful treatment with peginterferon and ribavirin on the liver fibrosis course of HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index | 2013 |
The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Antiviral Agents; Decision Trees; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors | 2013 |
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Laparoscopy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Severity of Illness Index; Spleen; Splenectomy; Treatment Outcome; Ubiquitins | 2012 |
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Linear Models; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nuclear Proteins; Odds Ratio; Retrospective Studies; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome; Young Adult | 2013 |
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin D | 2013 |
Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2012 |
Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome | 2012 |
Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience.
Topics: Adult; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Reoperation; Ribavirin; Survival Rate; Treatment Outcome | 2012 |
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome | 2013 |
Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.
Topics: Antibodies; Antigens, Neoplasm; Antiviral Agents; Hepatitis C, Chronic; Humans; Immunoassay; Interferon-alpha; Lectins; Liver Cirrhosis; Membrane Glycoproteins; Polyethylene Glycols; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin | 2013 |
[What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Waiting Lists | 2013 |
Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy.
Topics: Antineoplastic Agents; Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Forecasting; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Predictive Value of Tests; Ribavirin; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2002 |
[Treatment of hepatitis C: advances and consensus].
Topics: Aged; Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Consensus Development Conferences as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Paris; Research; Ribavirin; Risk Factors; Substance-Related Disorders | 2002 |
[Chronic hepatitis C virus infection: always treat!--Pro].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Ribavirin | 2002 |
[What therapy is meaningful in chronic hepatitis C and resection of hepatocellular carcinoma for recurrence prophylaxis?].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin | 2002 |
[Hepatitis C].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Diagnosis, Differential; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors | 2002 |
The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; RNA, Viral | 2003 |
Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit?
Topics: Adult; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure | 2003 |
[Is there a place for ribavirin in the treatment for renal transplant patients infected by hepatitis C virus?].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biopsy; Creatinine; Female; gamma-Glutamyltransferase; Hemoglobins; Hepatitis C; Humans; Kidney Transplantation; Liver; Liver Cirrhosis; Male; Middle Aged; Proteinuria; Ribavirin | 2003 |
[Antiviral treatment in liver cirrhosis due to hepatitis C virus].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Waiting Lists | 2003 |
Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors.
Topics: Adult; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2003 |
Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Topics: Adipokines; Adult; Antiviral Agents; Biomarkers; Chitinase-3-Like Protein 1; Female; Glycoproteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Middle Aged; Peptide Fragments; Predictive Value of Tests; Procollagen; Ribavirin; RNA, Viral; Severity of Illness Index; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2003 |
[A small-sized hepatocellular carcinoma].
Topics: Antineoplastic Agents; Antiviral Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Patient Selection; Ribavirin; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2003 |
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Liver Cirrhosis; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States | 2003 |
Reversal of cirrhosis: evidence-based medicine?
Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Body Mass Index; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Obesity; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure | 2003 |
Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2003 |
Reversibility of hepatitis C virus-related cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis, Viral, Human; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral | 2004 |
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2004 |
Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Determination of glycated hemoglobin in patients with advanced liver disease.
Topics: Antiviral Agents; Fructosamine; Glycated Hemoglobin; Hepatitis C, Chronic; Hepatitis, Chronic; Humans; Liver Cirrhosis; Ribavirin | 2004 |
Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sarcoidosis; Tattooing | 2004 |
[Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; False Negative Reactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases | 2004 |
Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
Topics: Alleles; Antiviral Agents; Apolipoproteins E; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; History, 16th Century; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Recurrence; Ribavirin | 2004 |
[Chronic hepatitis and cirrhosis caused by C virus before and after liver transplantation. Report of one case].
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Viral Load | 2004 |
Improvement of liver histopathology in patients with hepatitis C after interferon and ribavirin combination therapy.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Treatment of chronic hepatitis C in a patient with systemic lupus erythematosus.
Topics: Aged; Anemia; Antiviral Agents; Asthenia; Drug Therapy, Combination; Female; Headache; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Lupus Erythematosus, Systemic; Ribavirin | 2004 |
Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Middle Aged; Receptors, Interleukin; Receptors, Interleukin-10; Ribavirin | 2005 |
[Hepatitis C and HIV in Spanish prisons].
Topics: Adult; Antiviral Agents; Comorbidity; Female; Hepatitis C, Chronic; HIV Infections; HIV Seroprevalence; Hospitalization; Hospitals, Public; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prisoners; Prisons; Recombinant Proteins; Ribavirin; Seroepidemiologic Studies; Spain; Substance Abuse, Intravenous | 2005 |
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2005 |
Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Iron; Iron Overload; Kidney Transplantation; Liver; Liver Cirrhosis; Male; Middle Aged; Postoperative Complications; Ribavirin; Transferrin | 2005 |
Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Immunosuppressive Agents; Infections; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2005 |
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy.
Topics: Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2005 |
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Second thoughts about secondary analyses.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Research Design; Retrospective Studies; Ribavirin | 2005 |
Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Infarction; Interferon alpha-2; Interferon-alpha; Ischemia; Jejunum; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vasculitis | 2006 |
[The apoptosis of hepatic tissues in hepatitis C].
Topics: Adult; Antiviral Agents; Apoptosis; Biopsy, Needle; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Poland; Recombinant Proteins; Ribavirin; Severity of Illness Index; Tumor Suppressor Protein p53 | 2005 |
[Complications in a patient with liver cirrhosis and HCV coinfection during treatment with peginterferon and ribavirin].
Topics: Adolescent; Antiviral Agents; Biliary Atresia; Child; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Transplantation; Polyethylene Glycols; Portasystemic Shunt, Transjugular Intrahepatic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia; Treatment Outcome | 2005 |
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
Topics: Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Darbepoetin alfa; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2005 |
Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention; Time Factors; Treatment Outcome | 2005 |
[Retreatment of patients with chronic hepatitis C].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Retreatment; Ribavirin; Treatment Failure | 2005 |
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Black People; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Ribavirin; RNA, Viral; White People | 2006 |
Effect of anti-viral therapy for occult hepatitis C virus infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Confidence Intervals; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; In Situ Hybridization; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load | 2006 |
Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
Topics: Adjuvants, Immunologic; Antiviral Agents; Costs and Cost Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mexico; Polyethylene Glycols; Prospective Studies; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin | 2006 |
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Topics: Age Distribution; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2006 |
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Cholesterol, HDL; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Liver Cirrhosis; Living Donors; Male; Metabolic Syndrome; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Triglycerides | 2006 |
[Primer treatment of acute and chronic hepatitis C].
Topics: Acute Disease; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2006 |
Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Transplantation, Homologous; Viral Load; Viremia | 2006 |
Short-term treatment duration for HCV-2 and HCV-3 infected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Contraindications; Female; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Middle Aged; Peptide Fragments; Procollagen; Retrospective Studies; Ribavirin; Tissue Inhibitor of Metalloproteinase-1 | 2006 |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Autoantibodies; Disease Progression; Drug Therapy, Combination; gamma-Glutamyltransferase; Golgi Apparatus; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
The faster the better?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
Topics: Antiviral Agents; Brazil; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Liver Cirrhosis; Ribavirin; RNA, Viral; Viral Load | 2006 |
Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Viral Load | 2007 |
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention | 2007 |
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2006 |
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Topics: Adult; Age Factors; Aged; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Up-Regulation; Viral Load | 2007 |
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.
Topics: Adipocytes; Adult; Antiviral Agents; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Intra-Abdominal Fat; Liver Cirrhosis; Male; Middle Aged; Obesity; Recombinant Proteins; Ribavirin | 2007 |
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Circulation; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Venous Pressure; Viral Load; Virulence | 2007 |
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.
Topics: Antiviral Agents; Apoptosis; Genotype; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; RNA, Viral; Virus Replication | 2007 |
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy, Needle; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2006 |
[Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin].
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Poland; Ribavirin; Vascular Endothelial Growth Factor A | 2007 |
Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.
Topics: Antiviral Agents; Biomarkers; Child; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Poisson Distribution; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2007 |
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Time Factors | 2008 |
[The recurrence of hepatitis C virus after liver transplantation].
Topics: Adult; Antiviral Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reoperation; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Antiviral treatment of HCV-related cirrhosis.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2007 |
Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Female; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Liver Diseases; Male; Necrosis; Ribavirin; RNA, Viral; Transaminases; Viral Load | 2007 |
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferons; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Obesity; Ribavirin; Treatment Failure; Treatment Outcome | 2008 |
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2007 |
Summaries for patients. Sustained virologic response in hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus.
Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reoperation; Ribavirin; RNA, Viral; Secondary Prevention; Time Factors | 2007 |
[Chronic fatigue. IV--Assessment of a 40-year-old patient].
Topics: Adult; Anemia, Iron-Deficiency; Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Fatigue Syndrome, Chronic; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Methadone; Narcotics; Opioid-Related Disorders; Ribavirin; Thyroid Function Tests | 2007 |
[Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load | 2008 |
[Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project].
Topics: Antiviral Agents; Biopsy; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Health Status; Hepatitis C, Chronic; Humans; Insurance, Health; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Education as Topic; Prospective Studies; Quality of Life; Ribavirin; Self-Help Groups; Socioeconomic Factors; Surveys and Questionnaires; Time Factors | 2008 |
Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
Topics: Adult; Age Factors; Aged; Antiviral Agents; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Prevalence; Ribavirin; Risk Factors | 2008 |
PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Uric Acid; Viral Load | 2008 |
Hepatitis C virus cirrhosis: prolonged sustained virological response in a patient after low-dose antiviral treatment.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?
Topics: Antiviral Agents; Drug Administration Schedule; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Ribavirin; Statistics as Topic; Treatment Outcome | 2008 |
Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Azathioprine; Chronic Disease; Contraindications; Drug Therapy, Combination; Female; Hemoglobins; Hemolysis; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Retrospective Studies; Ribavirin | 1997 |
Efficacy of combined interferon and ribavirin for treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; Time Factors | 1998 |
Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.
Topics: Antiviral Agents; Drug Tolerance; Female; Glomerulonephritis; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nephrotic Syndrome; Recurrence; Ribavirin; Viremia | 1998 |
[Should we treat cirrhosis in hepatitis C carriers with antiviral agents?].
Topics: Antiviral Agents; Carrier State; Combined Modality Therapy; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Patient Selection; Ribavirin | 1999 |
The treatment of hepatitis C.
Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Prevalence; Ribavirin | 1999 |
[Severe relapse of hepatitis C following liver transplantation. Successful treatment with a combination of interferon-alpha and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Treatment Outcome | 1999 |
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.
Topics: Adolescent; Adult; Agammaglobulinemia; Antiviral Agents; Common Variable Immunodeficiency; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin | 1999 |
[Hepatitis C. Saving the liver].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 1999 |
[Treatment and prevention of hepatitis C].
Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin | 2000 |
Ribavirin: new preparation. An advance, but still no cure-all.
Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; United States | 2000 |
Managing chronic hepatitis C acquired through intravenous drug use.
Topics: Adolescent; Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome | 2001 |
Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2001 |
Hepatitis C: who should you treat and how?
Topics: Amantadine; Antiviral Agents; Decision Making; Decision Trees; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Diseases; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Protective Agents; Ribavirin; Silymarin | 2001 |
Liver biopsy in hepatitis C: reassessing its role in 2001.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2002 |
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Recombinant Proteins; Ribavirin | 2002 |
Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Lack of evidence for ribavirin-induced bone loss.
Topics: Bone Density; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Osteoporosis; Ribavirin | 2002 |